doc_id	sent_index	relation_id	relation	trigger	trigger_offset	arg_num	arg_base_np	arg_protein	arg_domain	arg_site	arg_sugar	PSource	SiteSource	NProtein	NID	SiteName	sent_text
33135055	7	8	gly	epitopes	948:955	arg1	hACE2	hACE2			epitopes	PUBTATOR		hACE2	59272		To deduce the detailed structure of glycan epitopes on hACE2 that may be involved in viral binding, we have characterized the terminal sialic acid linkages, the presence of bisecting GlcNAc and the pattern of N-glycan fucosylation.
29793953	11	67	gly	nonglycosylated	2201:2215	arg1	nonglycosylated NTCP	nonglycosylated NTCP				PUBTATOR		NTCP	6554		We found differentiated HepaRG cells expressed nonglycosylated NTCP despite a wild-type coding sequence.
31336250	5	5	gly	glycosylated	1181:1192	arg1	wild-type glycosylated Fc	wild-type glycosylated Fc				Cterm		Fc			High-throughput screening of the resulting library led to the identification of an aglycosylated Fc variant that exhibited almost double the antibody-dependent cell-mediated cytotoxicity than wild-type glycosylated Fc.
30713024	0	17	gly	OGT-tolerated	16:28	arg1	Ac4GlcNAcF3	OGT			Ac4GlcNAcF3	PUBTATOR		OGT	108155		Ac4GlcNAcF3, an OGT-tolerated but OGA-resistant regulator for O-GlcNAcylation.
30713024	0	27	gly	OGA-resistant	34:46	arg1	Ac4GlcNAcF3	OGA			Ac4GlcNAcF3	PUBTATOR		OGA	76055		Ac4GlcNAcF3, an OGT-tolerated but OGA-resistant regulator for O-GlcNAcylation.
29718541	3	12	gly	glycoproteins	665:677	arg1	the Nox5-related oxidase Nox2	the Nox5-related oxidase Nox2				PUBTATOR		Nox2	1536		In contrast, Sar1 (H79G) effectively inhibits ER-to-Golgi transport of glycoproteins including the Nox5-related oxidase Nox2.
31616924	10	43	gly	glycoforms	1708:1717	arg1	tissue-specific APOE glycoforms	tissue-specific APOE glycoforms				PUBTATOR		APOE	348		These data, although limited by sample size, suggest that there are tissue-specific APOE glycoforms.
31371405	4	52	gly	N-glycosylated	844:857	arg1	DDR-2	DDR-2				PUBTATOR		DDR-2	180622		Furthermore, we found that DDR-2 is N-glycosylated at the Asn-141 residue located in its discoidin domain, and mutation of this residue caused an axon regeneration defect.
32109505	0	81	gly	N-glycosylation	0:14	arg1	TRPM8 protein	TRPM8 protein				PUBTATOR		TRPM8 protein	79054		N-glycosylation state of TRPM8 protein revealed by terahertz spectroscopy and molecular modelling.
31672932	8	51	gly	glycosylation	1104:1116	arg1	RIPK3	RIPK3				PUBTATOR		RIPK3	56532		Furthermore, glycosylation of RIPK3 by OGT is associated with reduced RIPK3 protein stability.
30853938	7	27	gly	glycosylates	971:982	arg1	cyclin D1	cyclin D1				PUBTATOR		cyclin D1	595		Finally, biochemical and cell imaging experiments in human cancer cells reveal that the O-GlcNAc transferase (OGT) binds to and glycosylates cyclin D1.
29755357	0	38	gly	N-Glycosylation	0:14	arg1	Lipocalin 2	Lipocalin 2				PUBTATOR		Lipocalin 2	3934		N-Glycosylation of Lipocalin 2 Is Not Required for Secretion or Exosome Targeting.
32282299	6	39	gly	N-glycosylation	1130:1144	arg1	IgA1	IgA1				PUBTATOR		IgA1	P01876		METHODS Capillary electrophoresis with laser induced fluorescent detection (CE-LIF) was used to analyze the N-glycosylation profiles of Z(IgA1) partitioned immunoglobulin A in pooled serum and saliva of 10 control subjects and 8 patients with malignant hematological diseases having cytostatic treatment induced mild oral mucosal lesions.
29784879	0	22	gly	protein	117:123	arg1	the mannose-trimming activity	ER degradation-enhancing α-mannosidase-like protein 3			the mannose-trimming activity	PUBTATOR		ER degradation-enhancing α-mannosidase-like protein 3	80267		ER-resident protein 46 (ERp46) triggers the mannose-trimming activity of ER degradation-enhancing α-mannosidase-like protein 3 (EDEM3).
30623643	4	56	gly	glycoproteins	621:633	arg1	Mucin glycoproteins	Mucin glycoproteins				PUBTATOR		Mucin glycoproteins	100508689		Mucin glycoproteins, for example, comprise an abundant source of carbon in the gut, oral cavity, respiratory tract, and other mucosal surfaces but are not commercially available.
31029427	8	6	gly	sites	1339:1343	arg1	FOXA1	FOXA1			sites	PUBTATOR		FOXA1	3169		Through an ESI-MS assay, S354 and S355 were identified as probable O-GalNAcylation sites on FOXA1.
31511323	0	80	gly	N-Glycosylation	0:14	arg1	the voltage-gated sodium channel β2 subunit	the voltage-gated sodium channel β2 subunit				PUBTATOR		2 subunit	170589		N-Glycosylation of the voltage-gated sodium channel β2 subunit is required for efficient trafficking of NaV1.5/β2 to the plasma membrane.
29237830	4	12	gly	glycosylation	520:532	arg1	DG	DG				Cterm		DG	1605		Interestingly, functional glycosylation of DG does not always correlate with viral tropism observed in vivo The broadly expressed phosphatidylserine (PS) receptors Axl and Tyro3 were recently identified as alternative LASV receptor candidates.
34662441	3	87	gly	glycoforms	570:579	arg1	PSMA	PSMA				PUBTATOR		PSMA	2346		METHODS Mass spectrometry was used to analyze the distribution of the site-specific glycoforms of PSMA in insect, human embryonic kidney, and prostate cancer cells, and in prostate tissue upon immunoaffinity enrichment.
30504678	0	36	gly	Glycosylation	102:114	arg1	Intercellular Adhesion Molecule-1	Intercellular Adhesion Molecule-1				OGER		Intercellular Adhesion Molecule-1	P05362		Asiatic Acid, Corosolic Acid, and Maslinic Acid Interfere with Intracellular Trafficking and N-Linked Glycosylation of Intercellular Adhesion Molecule-1.
32168410	11	83	gly	FXIII-B	1267:1273	arg1	The total N-glycan profile	FXIII-B			The total N-glycan profile	PUBTATOR		FXIII-B	2165		The total N-glycan profile of FXIII-B featured nine individual structures; three were fucosylated and each structure contained at least one sialic acid.
29577901	7	4	gly	peptide	1195:1201	arg1	ncOGT	OGT			peptide	PUBTATOR		OGT	108155		Moreover, we map two new O-GlcNAc sites in the longest OGT isoform (ncOGT): S437 in the tetratricopeptide repeat (TPR) 13 domain and T1043 in the far C-terminus, and a new O-GlcNAc modified peptide (amino acids 826-832) in the intervening region (Int-D) within the catalytic domain.
29577901	7	4	gly	peptide	1195:1201	arg1	the longest OGT isoform	OGT isoform			peptide	PUBTATOR		OGT isoform	8473		Moreover, we map two new O-GlcNAc sites in the longest OGT isoform (ncOGT): S437 in the tetratricopeptide repeat (TPR) 13 domain and T1043 in the far C-terminus, and a new O-GlcNAc modified peptide (amino acids 826-832) in the intervening region (Int-D) within the catalytic domain.
29577901	7	70	gly	sites	1039:1043	arg1	ncOGT	OGT			sites	PUBTATOR		OGT	108155		Moreover, we map two new O-GlcNAc sites in the longest OGT isoform (ncOGT): S437 in the tetratricopeptide repeat (TPR) 13 domain and T1043 in the far C-terminus, and a new O-GlcNAc modified peptide (amino acids 826-832) in the intervening region (Int-D) within the catalytic domain.
29577901	7	70	gly	sites	1039:1043	arg1	the longest OGT isoform	OGT isoform			sites	PUBTATOR		OGT isoform	8473		Moreover, we map two new O-GlcNAc sites in the longest OGT isoform (ncOGT): S437 in the tetratricopeptide repeat (TPR) 13 domain and T1043 in the far C-terminus, and a new O-GlcNAc modified peptide (amino acids 826-832) in the intervening region (Int-D) within the catalytic domain.
29577901	2	57	gly	modified	315:322	arg1	LXRα AND O-linked β-N-acetyl-glucosamine	LXRα			O-linked β-N-acetyl-glucosamine	PUBTATOR		LXRα 	10062		We have previously shown that LXRα is post-translationally modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) with increased transcriptional activity.
29577901	2	57	gly	modified	315:322	arg3	LXRα AND O-GlcNAc	LXRα			O-GlcNAc	PUBTATOR		LXRα 	10062		We have previously shown that LXRα is post-translationally modified by O-linked β-N-acetyl-glucosamine (O-GlcNAc) with increased transcriptional activity.
34128680	5	56	gly	NQ11	971:974	arg1	N(GlcNAc)SGSG-Q11	NQ11			N(GlcNAc)SGSG-Q11	Cterm		NQ11			Specifically, an NQ11 variant modified with N-linked N-acetylglucosamine, N(GlcNAc)SGSG-Q11 (GQ11), formed β-sheet nanofibers more slowly than NQ11 in deionized water (pH 5.8), which correlated to the tendency of GQ11 to form a combination of short fibrils and nonfibrillar aggregates, whereas NQ11 formed extended nanofibers.
34774484	0	75	gly	N-glycosylation	0:14	arg1	Trop2	Trop2				PUBTATOR		Trop2	4070		N-glycosylation status of Trop2 impacts its surface density, interaction with claudin-7 and exosomal release.
29269413	4	40	gly	β1,4-galactosyltransferase	641:666	arg1	β1,4GalTV	1,4-galactosyltransferase V			β1,4GalTV	PUBTATOR		1,4-galactosyltransferase V	9334		We have previously reported that β1,4-galactosyltransferase V (β1,4GalTV), which galactosylates the GlcNAcβ1-6Man arm of the branched N-glycans, is highly expressed in glioma and promotes glioma cell growth in vitro and in vivo However, the mechanism by which β1,4GalTV stimulates glioma growth is unknown.
31616924	3	67	gly	O-glycosylation	536:550	arg1	APOE	APOE				PUBTATOR		APOE	348		To better understand the O-glycosylation on this critical molecule and differences across tissues, we analyzed the O-glycosylation on APOE isolated from the plasma and CSF of aged individuals.
31164864	8	42	gly	TxNIP	1322:1326	arg1	O-GlcNAcylation	TxNIP			O-GlcNAcylation	PUBTATOR		TxNIP	117514		Interestingly, expression and O-GlcNAcylation of TxNIP appeared to be increased in islets of diabetic rodents.
28528272	8	61	gly	cystatin	1218:1225	arg1	complex mannose-linked	cystatin E/M			complex mannose-linked	PUBTATOR		cystatin E/M	1474		The carbohydrates on legumain were shown to be of the hybrid or high mannose type, whereas cystatin E/M was characterized as complex mannose-linked.
28528272	8	95	gly	carbohydrates	1131:1143	arg1	legumain	legumain			carbohydrates	OGER		legumain	Q99538		The carbohydrates on legumain were shown to be of the hybrid or high mannose type, whereas cystatin E/M was characterized as complex mannose-linked.
32544330	5	16	gly	glycan	758:763	arg1	Asn88			Asn88	Asn88		AminoAcid			Asn88	In contrast, the glycan on Asn88 is flexible and can even enter the enzymic active site, hindering catalysis.
32858085	6	56	gly	non-glycosylated	1016:1031	arg1	M9GN2-RNase and non-glycosylated RNase A	M9GN2-RNase and non-glycosylated RNase A				PUBTATOR		RNase A	6035		RESULTS HUGT1 slightly accelerated the folding of M9GN2-RNase and non-glycosylated RNase A as the same extent.
31596566	5	12	gly	heterogeneity	871:883	arg1	the secreted IgG	IgG			heterogeneity	Cterm		IgG			Through iterative engineering and model refinement, we rationally increase the fraction of bigalactosylated glycans five-fold from 11.9% to 61.9% and simultaneously decrease the glycan heterogeneity on the secreted IgG.
29672582	3	62	gly	released	743:750	arg1	serum IgG4 AND N-glycan	serum IgG4			N-glycan	OGER		IgG4	P01861		This study determined the concentration of N-linked glycans (N-glycan) released from serum IgG4 in IgG4RD patients and compared the difference of glycosylation changes to those in healthy controls.
29672582	3	62	gly	released	743:750	arg2	serum IgG4 AND N-linked glycans	serum IgG4			N-linked glycans	OGER		IgG4	P01861		This study determined the concentration of N-linked glycans (N-glycan) released from serum IgG4 in IgG4RD patients and compared the difference of glycosylation changes to those in healthy controls.
30517873	3	44	gly	N-acetylglucosamine	500:518	arg1	the threonine 754 site			the threonine 754 site	the threonine 754 site		SpecificSite			threonine 754 site	Here, we provide evidence that ULK1 is the attachment of O-linked N-acetylglucosamine (O-GlcNAcylated) on the threonine 754 site by O-linked N-acetylglucosamine transferase (OGT) upon glucose starvation.
32028604	5	3	part_of	Gly116	1186:1191	arg1	AGX1/UAP1	AGX1		Gly116		PUBTATOR	AminoAcid	AGX1	6675	Gly116 and Lys127	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	3	part_of	Gly116	1186:1191	arg1	GALT	GALT		Gly116		PUBTATOR	AminoAcid	GALT	2592	Gly116 and Lys127	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	3	part_of	Gly116	1186:1191	arg1	UGP2	UGP2		Gly116		PUBTATOR	AminoAcid	UGP2	7360	Gly116 and Lys127	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	9	part_of	Lys127	1197:1202	arg1	AGX1/UAP1	AGX1		Lys127		PUBTATOR	AminoAcid	AGX1	6675	Gly116 and Lys127	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	9	part_of	Lys127	1197:1202	arg1	GALT	GALT		Lys127		PUBTATOR	AminoAcid	GALT	2592	Gly116 and Lys127	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	9	part_of	Lys127	1197:1202	arg1	UGP2	UGP2		Lys127		PUBTATOR	AminoAcid	UGP2	7360	Gly116 and Lys127	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	33	part_of	Ser192	1170:1175	arg1	AGX1/UAP1	AGX1		Ser192		PUBTATOR	AminoAcid	AGX1	6675	Trp190 and Ser192	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	33	part_of	Ser192	1170:1175	arg1	GALT	GALT		Ser192		PUBTATOR	AminoAcid	GALT	2592	Trp190 and Ser192	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	33	part_of	Ser192	1170:1175	arg1	UGP2	UGP2		Ser192		PUBTATOR	AminoAcid	UGP2	7360	Trp190 and Ser192	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	38	part_of	Trp190	1159:1164	arg1	AGX1/UAP1	AGX1		Trp190		PUBTATOR	AminoAcid	AGX1	6675	Trp190 and Ser192	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	38	part_of	Trp190	1159:1164	arg1	GALT	GALT		Trp190		PUBTATOR	AminoAcid	GALT	2592	Trp190 and Ser192	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
32028604	5	38	part_of	Trp190	1159:1164	arg1	UGP2	UGP2		Trp190		PUBTATOR	AminoAcid	UGP2	7360	Trp190 and Ser192	The computational docking studies supported the interaction of GAL-012 to the binding sites of GALT at Trp190 and Ser192, UGP2 at Gly116 and Lys127, and AGX1/UAP1 at Asn327 and Lys407, respectively.
31019513	5	106	gly	glycosylated	1024:1035	arg1	CD22	CD22				PUBTATOR		CD22	933		CD22 is highly glycosylated, containing 12 N-linked glycosylation sites on its extracellular domain, the function of which remain to be resolved.
30040982	3	5	gly	site	416:419	arg1	RET	RET			site	PUBTATOR		RET	5979		Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
30040982	3	5	gly	site	416:419	arg1	GFRA1	GFRA1			site	PUBTATOR		GFRA1	2674		Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
30040982	3	24	gly	N-glycosylated	373:386	arg1	RET	RET				PUBTATOR		RET	5979		Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
30040982	3	24	gly	N-glycosylated	373:386	arg1	GFRA1	GFRA1				PUBTATOR		Both GFRA1	2674		Both GFRA1 and RET are membrane proteins which are N-glycosylated but no O-linked sialylation site on GFRA1 or RET has been reported.
28614667	6	2	part_of	N125	1087:1090	arg1	the CTR ECD	CTR ECD		N125		PUBTATOR	SpecificSite	CTR ECD	799	N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
28614667	6	10	part_of	N73	1082:1084	arg1	the CTR ECD	CTR ECD		N73		PUBTATOR	SpecificSite	CTR ECD	799	N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
28614667	6	51	part_of	N130	1097:1100	arg1	the CTR ECD	CTR ECD		N130		PUBTATOR	SpecificSite	CTR ECD	799	N73, N125, and N130	PNGase F-catalyzed removal of N-glycans at N73, N125, and N130 in the CTR ECD decreased peptide affinity ∼10-fold, whereas Endo H-catalyzed trimming of the N-glycans to single GlcNAc residues had no effect on peptide binding.
31881804	0	34	gly	NSL3	25:28	arg1	O-GlcNAc-Modification	NSL3			O-GlcNAc-Modification	PUBTATOR		NSL3	55683		O-GlcNAc-Modification of NSL3 at Thr755 Site Maintains the Holoenzyme Activity of MOF/NSL Histone Acetyltransfease Complex.
30127386	0	28	gly	eIF4GI	25:30	arg1	O-GlcNAc modification	eIF4GI			O-GlcNAc modification	PUBTATOR		eIF4GI	1981		O-GlcNAc modification of eIF4GI acts as a translational switch in heat shock response.
28679762	6	115	gly	glycosylated	1077:1088	arg1	AAVR	AAVR				PUBTATOR		AAVR	79932		While we find that AAVR is an N-linked glycosylated protein, this glycosylation is not a strict requirement for AAV2 binding or functional transduction.
30158294	5	61	gly	modified	626:633	arg1	virion-associated SERINC5 AND N-linked, complex glycans	virion-associated SERINC5			N-linked, complex glycans	PUBTATOR		SERINC5	256987		We used various glycosidases to establish that virion-associated SERINC5 is modified by N-linked, complex glycans, whereas the majority of SERINC5 in cells is of relatively low molecular weight and is modified by high-mannose glycans.
33073996	4	40	gly	carries	547:553	arg1	PD-L1 AND mostly complex glycans	PD-L1			mostly complex glycans	PUBTATOR		PD-L1	29126		We demonstrate that PD-L1 on the surface of breast cancer cell line carries mostly complex glycans with a high proportion of polyLacNAc structures at the N219 sequon.
30796923	7	23	gly	HDAC6	836:840	arg1	O-GlcNAcylation	HDAC6			O-GlcNAcylation	PUBTATOR		HDAC6	10013		In vitro enzymatic assays showed that O-GlcNAcylation of either tubulin or HDAC6 promoted microtubule disassembly, which likely in turn caused ciliary shortening.
29793953	12	25	gly	glycosylated	2294:2305	arg1	NTCP	NTCP				PUBTATOR		NTCP	6554		NTCP introduced to HepG2 cells was glycosylated at two N-linked glycosylation sites, but mutating either or both sites failed to prevent infection by cell culture-derived HBV or to confer susceptibility to serum-derived HBV.
34726367	4	31	gly	PglI	666:669	arg1	GlcTF	PglI			GlcTF	Cterm		PglI			Although all 4 strains encode the PglI glucosyltransferase (GlcTF), one aspartate in the DXDD motif was missing, an alteration also present in ∼4% of all available PglI sequences.
31829588	1	13	gly	glycosylation	106:118	arg1	bovine lactoferrin	bovine lactoferrin				PUBTATOR		lactoferrin	280846		It has been reported previously that glycosylation of bovine lactoferrin changes over time.
31604106	8	14	gly	O-glycosylation	1517:1531	arg1	recombinant hCG protein	recombinant hCG protein				PUBTATOR		hCG protein	93659		The LC-MS/MS analysis and Phaseolus vulgaris leucoagglutinin (PHA-L) lectin blot analysis showed that Ugp2 overexpression significantly increased the total galactosylation levels of intracellular proteins and the O-glycosylation of recombinant hCG protein.
31186110	6	38	gly	α2b	1132:1134	arg1	human type N-glycans	IFN α2b			human type N-glycans	PUBTATOR		IFN α2b	3440		Heterogeneity of glycosylation and hypermannosylation in the wild-type strains of Pichia pastoris was circumvented by employing glycoengineered strain (SuperMan5) to produce glycosylated IFN α2b with human type N-glycans.
31186110	6	99	gly	glycosylated	1115:1126	arg1	glycosylated IFN α2b	glycosylated IFN α2b				PUBTATOR		IFN α2b	3440		Heterogeneity of glycosylation and hypermannosylation in the wild-type strains of Pichia pastoris was circumvented by employing glycoengineered strain (SuperMan5) to produce glycosylated IFN α2b with human type N-glycans.
31029427	6	69	gly	found	987:991	arg1	FOXA1 AND two O-GalNAcylation sites	FOXA1			two O-GalNAcylation sites	PUBTATOR		FOXA1	3169		By dividing and expressing recombinant FOXA1 as three segments, two O-GalNAcylation sites were found on FOXA1, both located at the C-terminal of the protein.
31913636	7	37	gly	glycoproteins	1534:1546	arg1	HIV Env	HIV Env				PUBTATOR		HIV Env	100616444		This reaction suggests that under certain experimental conditions, some glycoproteins can organize self-glycan addition, highlighting a remarkable self-assembly principle that may prove useful for re-engineering therapeutic glycoproteins such as influenza HA or HIV Env, where glycan sequence and structure can markedly affect bioactivity and vaccine efficacy.
32080177	4	31	gly	FUT8	550:553	arg1	a biantennary complex N-glycan	structure of FUT8			a biantennary complex N-glycan	PUBTATOR		structure of FUT8	2530		Here, we report the crystal structure of FUT8 complexed with GDP and a biantennary complex N-glycan (G0), which provides insight into both substrate recognition and catalysis.
29980609	1	17	gly	glycoproteins	123:135	arg1	AICL glycoproteins	AICL glycoproteins				PUBTATOR		AICL glycoproteins	9976		AICL glycoproteins are cognate activation-induced ligands of the C-type lectin-like receptor NKp80, which is expressed on virtually all mature human NK cells, and NKp80-AICL interaction stimulates NK cell effector functions such as cytotoxicity and cytokine secretion.
29672582	4	90	gly	glycoform	918:926	arg1	each IgG4 glycoform	each IgG4 glycoform				OGER		IgG4	P01861		We also compared the concentration of each IgG4 glycoform between patients with and without hypocomplementemia and individual organ involvement (kidney, pancreas, lymph node) in IgG4RD.
33664361	4	12	gly	glycosylated	629:640	arg1	NS1	NS1				PUBTATOR		NS1	5781		The viral non-structural protein 1 (NS1) was glycosylated exclusively with high-mannose structures on both potential N-glycosylation sites.
33908014	4	0	part_of	PNGase	644:649	arg1	NEB #P0710	Rapid™ PNGase F		NEB #P0710		PUBTATOR	SpecificSite	Rapid™ PNGase F	55768	P0710	The workflow described includes glycan release with Rapid™ PNGase F (NEB #P0710), direct labeling of released glycans with procainamide (PCA) or 2-aminobenzamide (2AB), cleanup of labeled glycans and a 3 h enzymatic digestion with exoglycosidases.
33908014	4	2	part_of	Rapid™	637:642	arg1	NEB #P0710	Rapid™ PNGase F		NEB #P0710		PUBTATOR	SpecificSite	Rapid™ PNGase F	55768	P0710	The workflow described includes glycan release with Rapid™ PNGase F (NEB #P0710), direct labeling of released glycans with procainamide (PCA) or 2-aminobenzamide (2AB), cleanup of labeled glycans and a 3 h enzymatic digestion with exoglycosidases.
33908014	4	42	part_of	NEB	654:656	arg1	NEB #P0710	NEB		NEB #P0710		OGER	SpecificSite	NEB	P20929	P0710	The workflow described includes glycan release with Rapid™ PNGase F (NEB #P0710), direct labeling of released glycans with procainamide (PCA) or 2-aminobenzamide (2AB), cleanup of labeled glycans and a 3 h enzymatic digestion with exoglycosidases.
29562282	8	47	gly	glycoprotein	1245:1256	arg1	NUP62	NUP62				OGER		NUP62	P37198		Confocal imaging shows that AANL co-localizes extensively with NUP62, a heavily O-GlcNAcylated and abundant nuclear pore glycoprotein.
31892091	2	40	gly	O126-glycopeptide	397:413	arg1	rhEPO	rhEPO				OGER		rhEPO	P29676		The O126-glycopeptide of rhEPO was used to optimize the methodology given its importance in quality control of biopharmaceuticals and doping analysis.
30487799	0	88	gly	IgM	60:62	arg1	Site-Specific N-Glycan Characterization	Grass Carp Serum IgM			Site-Specific N-Glycan Characterization	OGER		Grass Carp Serum IgM	Q15327		Site-Specific N-Glycan Characterization of Grass Carp Serum IgM.
34523671	3	44	gly	O-glycosylated	884:897	arg1	the naturally O-glycosylated human interferon α-2b	the naturally O-glycosylated human interferon α-2b				PUBTATOR		interferon α-2b	3440		Using RP-HPLC with a novel phenyl bonded phase to resolve intact protein glycoforms, the effect of sequon mutation on O-glycosylation initiation was examined through in vitro modification of the naturally O-glycosylated human interferon α-2b, and a sequon engineered human growth hormone.
28187132	3	25	gly	O-glycosylation	683:697	arg1	IgA1	IgA1				PUBTATOR		IgA1	P01876		These genes encode molecular partners essential for enzymatic O-glycosylation of IgA1.
30217930	7	20	gly	glycosylation	1507:1519	arg1	NIS	NIS				PUBTATOR		NIS	6528		Moreover, PTEN or PI3K/AKT/mTOR signaling could affect DPAGT1, a glycosylating enzyme involved in the initial step of N-linked glycosylation, to inhibit glycosylation of NIS.
33340519	4	26	gly	glycosylation	609:621	arg1	ACE2	ACE2				OGER		ACE2	Q9BYF1		We therefore sought to investigate whether the glycosylation state of ACE2 impacts the interaction with SARS-CoV-2 viral spike.
36303733	1	49	gly	protein	181:187	arg1	N-glycan structure	S) protein			N-glycan structure	OGER		S) protein	P04004		Background: The N-glycan structure and composition of the spike (S) protein of SARS-CoV-2 are pertinent to vaccine development and efficacy.
30135544	2	26	gly	glycosylation	241:253	arg1	prion protein	prion protein				PUBTATOR		prion protein	5621		The effects of glycosylation on prion protein (PrP) structure and function have not been thoroughly elucidated to date.
30135544	2	26	gly	glycosylation	241:253	arg1	PrP	PrP				PUBTATOR		PrP	5621		The effects of glycosylation on prion protein (PrP) structure and function have not been thoroughly elucidated to date.
30982611	3	4	part_of	GPI	697:699	arg1	Ser529	GPI		Ser529		OGER	AminoAcid	GPI	P06744	Ser529	This variant, located in the final exon of GPC4, results in premature termination of the protein 51 amino acid residues prior to the stop codon, and in concomitant loss of functionally important N-linked glycosylation (Asn514) and glycosylphosphatidylinositol (GPI) anchor (Ser529) sites.
28614667	4	22	gly	glycoforms	693:702	arg1	ECD	ECD				OGER		ECD	O95905		Here, we define the role of CTR N-glycosylation in hormone binding using purified calcitonin and amylin receptor extracellular domain (ECD) glycoforms and fluorescence polarization/anisotropy and isothermal titration calorimetry peptide-binding assays.
31600726	0	85	gly	glycoforms	16:25	arg1	Recombinant FSH glycoforms	Recombinant FSH glycoforms				PUBTATOR		FSH	14308		Recombinant FSH glycoforms are bioactive in mouse preantral ovarian follicles.
31783892	0	28	gly	glycosylation	10:22	arg1	PD-1	PD-1				OGER		PD-1	Q15116		Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity.
29933399	3	60	gly	glycoprotein	303:314	arg1	Env	Env				PUBTATOR		Env	155971		The HIV-1 envelope glycoprotein (Env) is the sole viral target of bnAbs, but is also targeted by binding, non-neutralizing antibodies.
29933399	3	60	gly	glycoprotein	303:314	arg1	The HIV-1 envelope glycoprotein	The HIV-1 envelope glycoprotein				PUBTATOR		envelope glycoprotein	155971		The HIV-1 envelope glycoprotein (Env) is the sole viral target of bnAbs, but is also targeted by binding, non-neutralizing antibodies.
31616924	4	27	gly	glycoforms	822:831	arg1	APOE	APOE				PUBTATOR		APOE	348		Detailed LC-MS/MS analyses allowed the identification of the glycosite and the attached glycan and site occupancy for all detectable glycosites on APOE and further three-dimensional modeling of physiological glycoforms of APOE.
33340519	2	46	gly	has	301:303	arg1	SARS-CoV-2 AND the capacity to bind sialic acid which is a common, and highly variable, terminal modification of glycans	SARS-CoV-2			the capacity to bind sialic acid which is a common, and highly variable, terminal modification of glycans	OGER		SARS	P49591		One potential contribution are differences in the glycosylation of target human cells, particularly as SARS-CoV-2 has the capacity to bind sialic acid which is a common, and highly variable, terminal modification of glycans.
30587575	8	41	gly	paxillin	1185:1192	arg1	The O-GlcNAcylation levels	paxillin			The O-GlcNAcylation levels	PUBTATOR		paxillin	5829		The O-GlcNAcylation levels of paxillin, talin, and focal adhesion kinase were down-regulated in KD cells.
30619781	5	35	gly	glycosylation	854:866	arg1	the tumor necrosis factor receptor type 1-associated DEATH domain protein	the tumor necrosis factor receptor type 1-associated DEATH domain protein				PUBTATOR		tumor necrosis factor receptor type 1-associated DEATH domain protein	8717		Addition of these compounds to cultured mammalian cells was sufficient to inhibit NleB1 glycosylation of the tumor necrosis factor receptor type 1-associated DEATH domain protein.
30529011	7	48	gly	phosphoglycoprotein	815:833	arg1	The SIBLING, matrix extracellular phosphoglycoprotein	The SIBLING, matrix extracellular phosphoglycoprotein				OGER		SIBLING, matrix extracellular phosphoglycoprotein	Q9NQ76		The SIBLING, matrix extracellular phosphoglycoprotein with ASARM motif (MEPE) is highly overexpressed in both BSP-/- and DKO and may impair mineralization through liberation of its ASARM (Acidic Serine-Aspartate Rich MEPE associated) peptides.
30740857	3	5	gly	glycans	294:300	arg1	FVIII	FVIII			glycans	OGER		FVIII	P00451		CLEC4M binds to mannose-containing glycans on FVIII.
31302509	7	25	gly	glycosylated	1033:1044	arg1	XPR1 receptors	XPR1 receptors				PUBTATOR		XPR1 receptors	Q9UBH6		While this substitution introduces an N-linked glycosylation site, XPR1 receptors are not glycosylated indicating that this replacement alters the virus-receptor interface independently of glycosylation.
29070692	9	75	gly	glycoproteins	1735:1747	arg1	Gc	Gc				Cterm		Gc			The M segment of the virus encodes a polyprotein precursor that is cleaved into two glycoproteins, Gn and Gc.
33556394	10	37	gly	β1AR	1882:1885	arg1	a structural determinant	1AR			a structural determinant	PUBTATOR		1AR	153		These studies identify the β1AR N-terminus as a structural determinant of β1AR responses that can be targeted for therapeutic advantage.
33177111	0	33	gly	CD55	15:18	arg1	Sialylation	CD55			Sialylation	OGER		CD55	P08174		Sialylation of CD55 by ST3GAL1 Facilitates Immune Evasion in Cancer.
31800099	2	29	gly	glycosylation	386:398	arg1	B4GALT1	B4GALT1				PUBTATOR		B4GALT1	2683		We set out to further investigate this by studying the effects of defective glycosylation on plasma lipids in patients with B4GALT1-CDG, caused by a mutation in B4GALT1 with defective N-linked glycosylation.
30888807	9	40	gly	had	1415:1417	arg1	P25 and anatase NPs AND higher protein and polysaccharide affinities	NPs			higher protein and polysaccharide affinities	OGER		NPs	P0C0P6		P25 and anatase NPs had higher protein and polysaccharide affinities, while rutile NPs exhibited stronger attachment onto phospholipids.
34379416	5	49	gly	glycosylated	824:835	arg1	glycosylated and unglycosylated yPDI	glycosylated and unglycosylated yPDI				Cterm		yPDI	64714		We compare simulations of glycosylated and unglycosylated yPDI and find that the presence of glycan-glycan and glycan-protein interactions influences the flexibility of PDI in different ways.
34379416	5	52	gly	unglycosylated	841:854	arg1	glycosylated and unglycosylated yPDI	glycosylated and unglycosylated yPDI				Cterm		yPDI	64714		We compare simulations of glycosylated and unglycosylated yPDI and find that the presence of glycan-glycan and glycan-protein interactions influences the flexibility of PDI in different ways.
31862392	12	29	gly	PAO1	1921:1924	arg1	extracellular polysaccharides	PAO1			extracellular polysaccharides	OGER		PAO1	Q9NWM0		The MELE diminished the production of virulence factors, including pyocyanin, protease, elastase, rhamnolipids, and extracellular polysaccharides of P. aeruginosa PAO1 in a concentration-dependent manner.
34917767	8	65	gly	ST3GAL5	1257:1263	arg1	GM3	ST3GAL5			GM3	PUBTATOR		ST3GAL5	8869		Quantitative plasma GSL profiles discriminated among ST3GAL5 genotypes: GM3 and GD3 were undetectable in ST3GAL5 c.694C > T homozygotes, who had markedly elevated lactosylceramide (19.17 ± 4.20 nmol/ml) relative to heterozygous siblings (9.62 ± 2.46 nmol/ml) and wild type controls (6.55 ± 2.16 nmol/ml).
34917767	8	65	gly	ST3GAL5	1257:1263	arg1	GD3	ST3GAL5			GD3	PUBTATOR		ST3GAL5	8869		Quantitative plasma GSL profiles discriminated among ST3GAL5 genotypes: GM3 and GD3 were undetectable in ST3GAL5 c.694C > T homozygotes, who had markedly elevated lactosylceramide (19.17 ± 4.20 nmol/ml) relative to heterozygous siblings (9.62 ± 2.46 nmol/ml) and wild type controls (6.55 ± 2.16 nmol/ml).
31616924	7	63	gly	glycosylated	1108:1119	arg1	CSF	CSF				OGER		CSF			APOE was hinge domain glycosylated (Thr194 and Ser197) in both CSF (27.3%) and plasma (10.3%).
31616924	7	63	gly	glycosylated	1108:1119	arg1	APOE	APOE				PUBTATOR		APOE	348		APOE was hinge domain glycosylated (Thr194 and Ser197) in both CSF (27.3%) and plasma (10.3%).
34192331	9	8	gly	IgGs	1480:1483	arg1	tri- and tetra-antennary N-glycans	IgGs			tri- and tetra-antennary N-glycans	Cterm		IgGs			Concerning the Fc-mediated effector functions, the majority of IgGs with tri- and tetra-antennary N-glycans on their Fc region showed properties similar to IgGs with ordinary bi-antennary N-glycans.
34192331	9	44	gly	IgGs	1573:1576	arg1	ordinary bi-antennary N-glycans	IgGs			ordinary bi-antennary N-glycans	Cterm		IgGs			Concerning the Fc-mediated effector functions, the majority of IgGs with tri- and tetra-antennary N-glycans on their Fc region showed properties similar to IgGs with ordinary bi-antennary N-glycans.
33103998	1	6	gly	glycosylated	194:205	arg1	its primary receptor ACE2	its primary receptor ACE2				OGER		ACE2	Q9BYF1		The Spike protein of SARS-CoV-2, its receptor-binding domain (RBD), and its primary receptor ACE2 are extensively glycosylated.
33103998	1	6	gly	glycosylated	194:205	arg1	SARS-CoV-2	SARS-CoV-2				OGER		SARS	P49591		The Spike protein of SARS-CoV-2, its receptor-binding domain (RBD), and its primary receptor ACE2 are extensively glycosylated.
30633504	0	49	gly	N-Glycosylation	31:45	arg1	Human Ribonuclease 1	Human Ribonuclease 1				OGER		Human Ribonuclease 1	P07998		Consequences of the Endogenous N-Glycosylation of Human Ribonuclease 1.
29717387	6	51	gly	unglycosylated	765:778	arg1	unglycosylated PPARγ	unglycosylated PPARγ				PUBTATOR		PPAR	Q07869		PPAR wild-type (WT) transfection inhibited the inflammatory activation of microglia, while the anti-inflammatory function of unglycosylated PPARγ was down-regulated.
30991145	4	25	part_of	Asp	849:851	arg1	G protein	G protein		Asp		OGER	AminoAcid	G protein		position 56, 379, 401, and 438 Asp	In this study, we predicted four N-linked glycosylation sites at position 56, 379, 401, and 438 Asp (N) in G protein, and using a reverse genetics system developed in our laboratory, constructed nine recombinant viruses with single, triple, or quadruple glycosylation site disruptions using alanine substitutions in the following combinations: rIHNV-N56A, rIHNV-N379A, rIHNV-N401A, rIHNV-N438A, rIHNV-N56A-N379A-N401A, rIHNV-N56A-N379A-N438A, rIHNV-N56A-N401A-N438A, rIHNV-N379A-N401A-N438A, and rIHNV-N56A-N379A-N401A-N438A.
34768939	5	29	gly	glycosylation	620:632	arg1	the ACE2 receptor	the ACE2 receptor				PUBTATOR		ACE2 receptor	59272		We further report that glycosylation of the ACE2 receptor enhances SARS-CoV-2 infectivity.
31029427	0	29	gly	s	43:43	arg1	FOXA1	FOXA1			s	PUBTATOR		FOXA1	3169		Identification of the O-GalNAcylation site(s) on FOXA1 catalyzed by ppGalNAc-T2 enzyme in vitro.
30158294	6	11	part_of	site	877:880	arg1	SERINC5	SERINC5		site		PUBTATOR	SpecificSite	SERINC5	256987	site, N294	Sequence alignment of SERINC family proteins led us to identify a conserved N-glycosylation site, N294, in SERINC5.
29454068	16	65	gly	receptor	2285:2292	arg1	Increased O-GlcNAcylation	receptor for activated C-kinase 1			Increased O-GlcNAcylation	PUBTATOR		receptor for activated C-kinase 1	10399		Increased O-GlcNAcylation of ribosomal receptor for activated C-kinase 1 is positively correlated with tumor growth, metastasis and recurrence in patients with hepatocellular carcinoma.
29886537	6	52	gly	sialylation	907:917	arg1	PrPSc	PrPSc				PUBTATOR		PrPSc	19122		For assessing sialylation status of PrPSc, we developed a reliable protocol that involves two-dimensional electrophoresis followed by Western blot (2D).
29886537	6	60	gly	PrPSc	929:933	arg1	sialylation status	PrPSc			sialylation status	PUBTATOR		PrPSc	19122		For assessing sialylation status of PrPSc, we developed a reliable protocol that involves two-dimensional electrophoresis followed by Western blot (2D).
30933973	9	83	gly	glycosylation	1826:1838	arg1	gp120	gp120				OGER		gp120	Q14624		Features predicting neutralization sensitivity or resistance included 26 surface-accessible residues in the VRC01 and CD4 binding footprints, the length of gp120, the length of Env, the number of cysteines in gp120, the number of cysteines in Env, and 4 potential N-linked glycosylation sites; the top features will be advanced to the primary sieve analysis.
28017896	13	32	gly	modified	2150:2157	arg3	Akt AND O-GlcNAcylation	Akt			O-GlcNAcylation	PUBTATOR		Akt	24185		We confirmed that Akt was modified by O-GlcNAcylation, and glucosamine pretreatment increased the O-GlcNAcylation of Akt.
28017896	13	46	gly	Akt	2241:2243	arg1	the O-GlcNAcylation	Akt			the O-GlcNAcylation	PUBTATOR		Akt	24185		We confirmed that Akt was modified by O-GlcNAcylation, and glucosamine pretreatment increased the O-GlcNAcylation of Akt.
30135544	3	53	gly	glycosylation	400:412	arg1	human PrP	human PrP				PUBTATOR		PrP	5621		In this study, we attempt to elucidate the effects of glycosylation on the aggregation and toxicity of human PrP.
33197804	11	71	gly	profiles	1536:1543	arg1	the SMG	SMG			profiles	OGER		SMG	P62309		CONCLUSION There are three secretory mucins with different glycan profiles in the SMG of mice, and their expression patterns change according to the period of the aging process.
34780171	8	58	gly	glycosylation	1815:1827	arg1	ERBB2	ERBB2				PUBTATOR		ERBB2	2064		Without the immunoprecipitation step, the large-scale glycoproteomic atlas also reveals site-specific glycosylation of many druggable receptor proteins, such as EGFR, MET, ERBB2, ERBB3, AXL, and IGF1R.
34780171	8	58	gly	glycosylation	1815:1827	arg1	IGF1R	IGF1R				PUBTATOR		IGF1R	3480		Without the immunoprecipitation step, the large-scale glycoproteomic atlas also reveals site-specific glycosylation of many druggable receptor proteins, such as EGFR, MET, ERBB2, ERBB3, AXL, and IGF1R.
34780171	8	58	gly	glycosylation	1815:1827	arg1	EGFR	EGFR				PUBTATOR		EGFR	1956		Without the immunoprecipitation step, the large-scale glycoproteomic atlas also reveals site-specific glycosylation of many druggable receptor proteins, such as EGFR, MET, ERBB2, ERBB3, AXL, and IGF1R.
34780171	8	58	gly	glycosylation	1815:1827	arg1	ERBB3	ERBB3				PUBTATOR		ERBB3	2065		Without the immunoprecipitation step, the large-scale glycoproteomic atlas also reveals site-specific glycosylation of many druggable receptor proteins, such as EGFR, MET, ERBB2, ERBB3, AXL, and IGF1R.
34780171	8	58	gly	glycosylation	1815:1827	arg1	AXL	AXL				PUBTATOR		AXL	558		Without the immunoprecipitation step, the large-scale glycoproteomic atlas also reveals site-specific glycosylation of many druggable receptor proteins, such as EGFR, MET, ERBB2, ERBB3, AXL, and IGF1R.
30919021	3	56	part_of	has	397:399	arg1	P4HA1 AND N259	P4HA1		N259		PUBTATOR	SpecificSite	P4HA1	18451	N259	P4HA1 has two glycosylation sites, Asn (N) 113 and N259.
31662433	5	29	gly	has	659:661	arg1	ATIII AND N-glycans	ATIII			N-glycans	PUBTATOR		ATIII	462		Although ATIII has N-glycans and a hydrophobic core, we found that its quality control depended solely on free thiol content.
31511323	11	14	gly	glycosylation	1654:1666	arg1	NaV1.5	NaV1.5				PUBTATOR		NaV1	Q8NEY1		In conclusion, our results indicate that N-linked glycosylation of β2 is required for surface localization of NaV1.5, a property that is often defective in inherited cardiac arrhythmias.
31511323	11	14	gly	glycosylation	1654:1666	arg1	β2	β2				PUBTATOR		2	170589		In conclusion, our results indicate that N-linked glycosylation of β2 is required for surface localization of NaV1.5, a property that is often defective in inherited cardiac arrhythmias.
34229070	11	8	gly	structures	1774:1783	arg1	APP	APP			structures	OGER		APP	P05067		GENERAL SIGNIFICANCE The accurate O-glycosites and O-glycan structures on APP may lead to a better understanding of the roles O-glycosylation plays in the processing and functions of APP.
30962950	4	14	gly	glycoprotein	733:744	arg1	Serum core fucosylated quiescin sulfhydryl oxidase 1	Serum core fucosylated quiescin sulfhydryl oxidase 1				PUBTATOR		sulfhydryl oxidase 1	5768		Serum core fucosylated quiescin sulfhydryl oxidase 1 (cf-QSOX1) was identified as a leading prognostic glycoprotein that significantly correlated with HCC recurrence.
30962950	4	73	gly	fucosylated	641:651	arg1	Serum core fucosylated quiescin sulfhydryl oxidase 1	Serum core fucosylated quiescin sulfhydryl oxidase 1				PUBTATOR		sulfhydryl oxidase 1	5768		Serum core fucosylated quiescin sulfhydryl oxidase 1 (cf-QSOX1) was identified as a leading prognostic glycoprotein that significantly correlated with HCC recurrence.
30962950	4	73	gly	fucosylated	641:651	arg1	cf-QSOX1	cf-QSOX1				PUBTATOR		QSOX1	104009		Serum core fucosylated quiescin sulfhydryl oxidase 1 (cf-QSOX1) was identified as a leading prognostic glycoprotein that significantly correlated with HCC recurrence.
34662441	9	21	gly	glycoforms	1768:1777	arg1	PSMA glycoforms	PSMA glycoforms				OGER		PSMA	Q04609		It will hopefully stimulate further research into PSMA glycoforms in the context of tumor staging, noninvasive detection of prostate tumors, and the impact of glycoforms on physicochemical and enzymatic characteristics of PSMA in a tissue-specific manner.
31186110	9	21	gly	glycosylated	1534:1545	arg1	glycosylated IFN α2b	glycosylated IFN α2b				PUBTATOR		IFN α2b	3440		Pharmacokinetic studies in Wistar rats revealed 1.3 fold increase in plasma half-life for glycosylated IFN α2b compared to standard IFN α2b produced by E. coli.
28931878	1	48	gly	glycans	99:105	arg1	immunoglobulin G	immunoglobulin G			glycans	Cterm		immunoglobulin G			N-linked glycans on immunoglobulin G (IgG) have been associated with pathogenesis of diseases and the therapeutic functions of antibody-based drugs; however, low-abundance species are difficult to detect.
28931878	1	48	gly	glycans	99:105	arg1	IgG	IgG			glycans	Cterm		IgG			N-linked glycans on immunoglobulin G (IgG) have been associated with pathogenesis of diseases and the therapeutic functions of antibody-based drugs; however, low-abundance species are difficult to detect.
34869209	1	57	gly	glycosylated	175:186	arg1	The SARS-CoV-2 spike protein	The SARS-CoV-2 spike protein				PUBTATOR		spike protein	43740568		The SARS-CoV-2 spike protein is heavily glycosylated, having 22 predicted N-glycosylation sites per monomer.
30709903	0	18	gly	O-glycosylated	120:133	arg1	O-glycosylated CREB	O-glycosylated CREB				PUBTATOR		CREB	12912		Iron down-regulates leptin by suppressing protein O-GlcNAc modification in adipocytes, resulting in decreased levels of O-glycosylated CREB.
31194940	1	39	gly	glycoprotein	156:167	arg1	Env	Env				PUBTATOR		Env)	155971		The fusion peptide (FP) of HIV-1 envelope glycoprotein (Env) is essential for mediating viral entry.
30158294	16	37	gly	N-glycosylation	2481:2495	arg1	SERINC5	SERINC5				PUBTATOR		SERINC5	256987		Nonetheless, N-glycosylation per se is neither required for the ability of SERINC5 to inhibit HIV-1 infectivity nor for its sensitivity to antagonism by Nef.
28344780	0	43	gly	glycosylation	9:21	arg1	Joubert syndrome type 10	Joubert syndrome type 10				PUBTATOR		Joubert syndrome type 10	8481		Abnormal glycosylation in Joubert syndrome type 10.
29980609	5	14	gly	glycoproteins	951:963	arg1	AICL glycoproteins	AICL glycoproteins				PUBTATOR		AICL glycoproteins	9976		Cys87 residing within the C-type lectin-like domain not only ensures stable homodimerization of AICL glycoproteins by disulfide bonding, but Cys87 is also required for efficient cell surface expression of AICL homodimers and essential for AICL-NKp80 interaction.
31308178	4	33	part_of	site	830:833	arg1	VEGFR2	VEGFR2		site		PUBTATOR	SpecificSite	VEGFR2	3791	Asn-247 site	Here, using glycoside hydrolase and kinase assays and immunoprecipitation and MS-based analyses, we demonstrate that N-linked glycans at the Asn-247 site in VEGFR2 hinder VEGF ligand-mediated receptor activation and signaling in endothelial cells.
30980499	8	69	gly	glycoproteins	1018:1030	arg1	transforming growth factor beta 1	transforming growth factor beta 1				PUBTATOR		transforming growth factor beta 1	7040		Collagens, proteoglycans, small integrin-binding ligand N-linked glycoproteins (SIBLINGs), and growth factors, such as COL1A1, biglycan, dentin sialoprotein, and transforming growth factor beta 1, were identified.
30980499	8	69	gly	glycoproteins	1018:1030	arg1	COL1A1	COL1A1				PUBTATOR		COL1A1	1277		Collagens, proteoglycans, small integrin-binding ligand N-linked glycoproteins (SIBLINGs), and growth factors, such as COL1A1, biglycan, dentin sialoprotein, and transforming growth factor beta 1, were identified.
30980499	8	69	gly	glycoproteins	1018:1030	arg1	dentin sialoprotein	dentin sialoprotein				PUBTATOR		dentin sialoprotein	1834		Collagens, proteoglycans, small integrin-binding ligand N-linked glycoproteins (SIBLINGs), and growth factors, such as COL1A1, biglycan, dentin sialoprotein, and transforming growth factor beta 1, were identified.
30980499	8	12	gly	N-linked	1009:1016	arg1	biglycan	N-linked			biglycan	Cterm		N-linked			Collagens, proteoglycans, small integrin-binding ligand N-linked glycoproteins (SIBLINGs), and growth factors, such as COL1A1, biglycan, dentin sialoprotein, and transforming growth factor beta 1, were identified.
32887075	7	78	part_of	had	1245:1247	arg1	the TNP-specific IgM AND an Asn-509 site	the TNP-specific IgM		an Asn-509 site		OGER	SpecificSite	TNP-specific IgM	P01871	Asn-509 site	Notably, the TNP-specific IgM had an Asn-509 site fully occupied with oligomannose, while only a small amount of oligomannose was found in the PBS-immunized IgM of this site.
30076101	1	48	gly	glycoprotein	280:291	arg1	Env	Env				PUBTATOR		Env	100616444		An important class of HIV-1 broadly neutralizing antibodies, termed the VRC01 class, targets the conserved CD4-binding site (CD4bs) of the envelope glycoprotein (Env).
30076101	1	48	gly	glycoprotein	280:291	arg1	the envelope glycoprotein	the envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		An important class of HIV-1 broadly neutralizing antibodies, termed the VRC01 class, targets the conserved CD4-binding site (CD4bs) of the envelope glycoprotein (Env).
28535613	7	13	gly	glycosylation	1268:1280	arg1	the purified rhBMP-4	the purified rhBMP-4				OGER		rhBMP-4	P12644		The N-terminal amino acid sequences and N-linked glycosylation of the purified rhBMP-4 were confirmed by N-terminal sequencing and de-N-glycosylation analysis, respectively.
34631661	8	129	part_of	122	1538:1540	arg1	N282	2		N122, N282 and N1158		PUBTATOR	SpecificSite	2	170589	N122, N282 and N1158	It was found that the N-glycosite at 1,158 position (N1158) and at 122, 282 and 1,158 positions (N122, N282 and N1158) were absent on S from CHO and HEK cells, respectively.
34631661	8	129	part_of	122	1538:1540	arg1	N122	2		N122, N282 and N1158		PUBTATOR	SpecificSite	2	170589	N122, N282 and N1158	It was found that the N-glycosite at 1,158 position (N1158) and at 122, 282 and 1,158 positions (N122, N282 and N1158) were absent on S from CHO and HEK cells, respectively.
34631661	8	129	part_of	122	1538:1540	arg1	N122	2		N122, N282 and N1158		PUBTATOR	SpecificSite	2	170589	N122, N282 and N1158	It was found that the N-glycosite at 1,158 position (N1158) and at 122, 282 and 1,158 positions (N122, N282 and N1158) were absent on S from CHO and HEK cells, respectively.
31527085	3	4	gly	observed	367:374	arg2	sOGT AND multiple O-GlcNAc sites	sOGT			multiple O-GlcNAc sites	Cterm		sOGT	8473		Recently, multiple O-GlcNAc sites have been observed on short-form OGT (sOGT) and nucleocytoplasmic OGT (ncOGT), both of which locate in the nucleus and cytoplasm in cell.
31527085	3	4	gly	observed	367:374	arg2	ncOGT AND multiple O-GlcNAc sites	ncOGT			multiple O-GlcNAc sites	Cterm		ncOGT	8473		Recently, multiple O-GlcNAc sites have been observed on short-form OGT (sOGT) and nucleocytoplasmic OGT (ncOGT), both of which locate in the nucleus and cytoplasm in cell.
31527085	3	4	gly	observed	367:374	arg2	nucleocytoplasmic OGT AND multiple O-GlcNAc sites	OGT			multiple O-GlcNAc sites	PUBTATOR		OGT	8473		Recently, multiple O-GlcNAc sites have been observed on short-form OGT (sOGT) and nucleocytoplasmic OGT (ncOGT), both of which locate in the nucleus and cytoplasm in cell.
32366695	3	9	gly	SARS-CoV-2	438:447	arg1	22 N-linked glycan sequons	SARS			22 N-linked glycan sequons	OGER		SARS	P49591		The SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in protein folding and immune evasion.
31133022	7	92	gly	glycans	1408:1414	arg1	GPI-APs	APs			glycans	OGER		APs	P07288		Notably, by coupling biochemical and computational studies, we propose a hypothetical mechanism that involves dual selective recognition and efficient binding dependent on both N-linked glycans on GPI-anchored proteins (GPI-APs) and sphingomyelin (SM) in lipid rafts.
34110173	3	7	gly	glycopeptides	603:615	arg1	erythropoietin	erythropoietin				PUBTATOR		erythropoietin	2056		Permethylated N-glycans, peptides, and enriched glycopeptides of erythropoietin were analyzed by nanoLC-MS/MS, and de-N-glycosylated erythropoietin was measured by LC-MS, enabling the qualitative and quantitative analysis of glycosylation and different glycan modifications (e.g., phosphorylation and O-acetylation).
34110173	3	50	gly	de-N-glycosylated	670:686	arg1	de-N-glycosylated erythropoietin	de-N-glycosylated erythropoietin				PUBTATOR		de-N-glycosylated erythropoietin	2056		Permethylated N-glycans, peptides, and enriched glycopeptides of erythropoietin were analyzed by nanoLC-MS/MS, and de-N-glycosylated erythropoietin was measured by LC-MS, enabling the qualitative and quantitative analysis of glycosylation and different glycan modifications (e.g., phosphorylation and O-acetylation).
34110173	3	79	gly	erythropoietin	620:633	arg1	Permethylated N-glycans	erythropoietin			Permethylated N-glycans	PUBTATOR		erythropoietin	2056		Permethylated N-glycans, peptides, and enriched glycopeptides of erythropoietin were analyzed by nanoLC-MS/MS, and de-N-glycosylated erythropoietin was measured by LC-MS, enabling the qualitative and quantitative analysis of glycosylation and different glycan modifications (e.g., phosphorylation and O-acetylation).
32172531	5	36	gly	glycosylation	827:839	arg1	hERG	hERG				PUBTATOR		hERG	2078		Furthermore, the protective effect of BeKm-1 on hERG from PK-cleavage was lost when glycosylation of hERG was inhibited.
31285765	11	37	gly	glycosylation	1429:1441	arg1	PCOLCE	PCOLCE				PUBTATOR		PCOLCE	5118		The overexpression of wild-type PCOLCE, but not its N29Q mutant, promoted migration, invasion and metastasis, indicating that the glycosylation of PCOLCE at Asn29 is necessary for its functions in osteosarcoma.
29454068	0	45	gly	RACK1	19:23	arg1	O-GlcNAcylation	RACK1			O-GlcNAcylation	PUBTATOR		RACK1	10399		O-GlcNAcylation of RACK1 promotes hepatocellular carcinogenesis.
31604106	12	1	gly	O-glycosylation	2268:2282	arg1	recombinant hCG protein	recombinant hCG protein				PUBTATOR		hCG protein	93659		The results indicated that Galnt1 overexpression increased the recombinant hCG protein level by 1.57 times and improved the total galactosylation of intracellular proteins, O-glycosylation and the stability of recombinant hCG protein.
34229070	6	1	gly	glycopeptides	948:960	arg1	APP	APP				OGER		APP	P05067		RESULTS A total of 14 O-glycosites were identified on three glycopeptides of APP, and at least four O-glycans including GalNAc (Tn antigen), core 1, and mono-/di-sialylated core 1 glycans were determinant at the residues of Thr576 and Thr577.
30956133	5	50	gly	hypersialylation	599:614	arg1	β1-integrin	β1-integrin				PUBTATOR		1-integrin	3688		Functional ST6Gal-I in exomeres can be transferred to cells, resulting in hypersialylation of recipient cell-surface proteins including β1-integrin.
33629527	6	54	gly	NA	1081:1082	arg1	N-glycan patterns	NA			N-glycan patterns	Cterm		NA	4758		As expected, N-glycan patterns of HA and NA from virus particles produced in both MDCK cell lines were similar.
30368301	5	104	gly	heterogeneity	884:896	arg1	hCG	hCG				OGER		hCG			As expected, CGE led to a better resolution than SDS-PAGE and confirmed the large heterogeneity of hCG.
33554253	6	38	gly	glycosylation	984:996	arg1	rIgGs	rIgGs				Cterm		IgGs	16059		In addition, the glycosylation pattern of rIgGs differs depending on the host cell used for expression.
29717387	5	48	gly	N-glycosylation	614:628	arg1	PPARγ	PPARγ				OGER		PPAR	Q07869		Disruption of both sites by site-directed mutagenesis completely abrogated the N-glycosylation of PPARγ.
36303733	7	73	gly	SARS-CoV-2	1343:1352	arg1	a substantially modified glycan profile	SARS			a substantially modified glycan profile	OGER		SARS	P49591		Blocking specific enzymes resulted in a substantially modified glycan profile of SARS-CoV-2.
31881804	9	53	part_of	NSL3	1432:1435	arg1	NSL3 Thr755 site	NSL3		NSL3 Thr755 site		PUBTATOR	AminoAcid	NSL3	55683	Thr755 site	Furthermore, O-GlcNAcylation of NSL3 Thr755 site regulates the histone H4 acetylation levels at lysine 5, 8, and 16, suggesting that the O-GlcNAcylation of NSL3 at Thr755 is required for maintaining the integrity and holoenzyme activity of the MOF/NSL complex.
34229070	8	40	gly	O-glycans	1401:1409	arg1	APP	APP			O-glycans	OGER		APP	P05067		Moreover, we also observed that TNF-α could upregulate the expression of APP and the truncated O-glycans on APP in HEK-293 T cell.
34229070	8	109	gly	APP	1379:1381	arg1	the truncated O-glycans	APP			the truncated O-glycans	OGER		APP	P05067		Moreover, we also observed that TNF-α could upregulate the expression of APP and the truncated O-glycans on APP in HEK-293 T cell.
29917166	2	18	gly	glycoproteins	261:273	arg1	osteopontin	osteopontin				PUBTATOR		osteopontin	6696		Studies have demonstrated that small integrin‑binding ligand N‑linked glycoproteins (SIBLINGs), particularly bone sialoprotein (BSP) and osteopontin (OPN), are involved in neoplastic growth and metastasis.
29917166	2	18	gly	glycoproteins	261:273	arg1	bone sialoprotein	bone sialoprotein				PUBTATOR		bone sialoprotein	3381		Studies have demonstrated that small integrin‑binding ligand N‑linked glycoproteins (SIBLINGs), particularly bone sialoprotein (BSP) and osteopontin (OPN), are involved in neoplastic growth and metastasis.
33554253	7	36	gly	rRb-IgGs	1126:1133	arg1	O-glycans	IgGs			O-glycans	Cterm		IgGs	16059		Therefore, we analyzed the N- and O-glycans of various rRb-IgGs expressed in HEK293 cells, detecting and quantifying 13 different N-glycan and 3 different O-glycan structures.
33554253	7	36	gly	rRb-IgGs	1126:1133	arg1	N-	IgGs			N-	Cterm		IgGs	16059		Therefore, we analyzed the N- and O-glycans of various rRb-IgGs expressed in HEK293 cells, detecting and quantifying 13 different N-glycan and 3 different O-glycan structures.
30550553	8	2	gly	has	1417:1419	arg1	GLTP AND a bound GlcCer	GLTP			a bound GlcCer	PUBTATOR		GLTP	51228		Here we found that if GLTP has a bound GlcCer the association with VAP-A is weaker.
30563903	6	8	gly	deglycosylation	1163:1177	arg1	fXII	fXII				OGER		fXII	P00748		At both sites, cleavage occurs between proline and an O-linked glycosylated threonine, and deglycosylation of fXII prevents cleavage by CpaA.
33554253	8	57	gly	glycosylation	1465:1477	arg1	the recombinant produced IgGs	the recombinant produced IgGs				Cterm		IgGs	16059		The distribution of the different detected glycoforms in our rRb-IgG N-glycan analysis is in agreement with previous studies on recombinant human IgG N-glycans, confirming the hypothesis that the host cell defines the glycosylation of the recombinant produced IgGs.
35140700	11	23	gly	sialylation	1710:1720	arg1	IgG	IgG				Cterm		IgG			Specifically, the results of lectin microarray showed the galactose level of IgG was increased by IFN-γ stimulation (p<0.05), and the sialylation of IgG was increased by IL-21 and IL-17A (p<0.05).
35140700	11	48	gly	IgG	1725:1727	arg1	the sialylation	IgG			the sialylation	Cterm		IgG			Specifically, the results of lectin microarray showed the galactose level of IgG was increased by IFN-γ stimulation (p<0.05), and the sialylation of IgG was increased by IL-21 and IL-17A (p<0.05).
35140700	11	49	gly	IgG	1653:1655	arg1	the galactose level	IgG			the galactose level	Cterm		IgG			Specifically, the results of lectin microarray showed the galactose level of IgG was increased by IFN-γ stimulation (p<0.05), and the sialylation of IgG was increased by IL-21 and IL-17A (p<0.05).
29805493	6	22	gly	SCP	653:655	arg1	The monosaccharide composition	SCP			The monosaccharide composition	OGER		SCP	Q9CXK4		The monosaccharide composition of SCP was determined by high-performance liquid chromatography.
33629527	8	32	gly	N-glycosylated	1386:1399	arg1	NA	NA				Cterm		NA	4758		In contrast, NA was found to be exclusively N-glycosylated at site N73.
30422384	7	70	gly	proMMP-9	1276:1283	arg1	larger oligosaccharides	MMP-9			larger oligosaccharides	OGER		MMP-9			Compared to recombinant Sf-9 proMMP-9 glycoforms, larger oligosaccharides of human neutrophil proMMP-9 increased resistance against proteolytic activation.
30422384	7	94	gly	glycoforms	1220:1229	arg1	recombinant Sf-9 proMMP-9 glycoforms	recombinant Sf-9 proMMP-9 glycoforms				OGER		MMP-9			Compared to recombinant Sf-9 proMMP-9 glycoforms, larger oligosaccharides of human neutrophil proMMP-9 increased resistance against proteolytic activation.
32172531	4	1	gly	glycosylated	616:627	arg1	normal glycosylated hERG channels	normal glycosylated hERG channels				PUBTATOR		hERG channels	2078		In the present study, our data revealed that, compared with normal glycosylated hERG channels, nonglycosylated hERG channels were significantly more susceptible to cleavage by extracellular PK.
32172531	4	52	gly	nonglycosylated	644:658	arg1	nonglycosylated hERG channels	nonglycosylated hERG channels				PUBTATOR		hERG channels	2078		In the present study, our data revealed that, compared with normal glycosylated hERG channels, nonglycosylated hERG channels were significantly more susceptible to cleavage by extracellular PK.
28368034	6	75	gly	modified	929:936	arg1	The plant-based S-hyIgA AND plant-specific N-linked sugar chains	The plant-based S-hyIgA			plant-specific N-linked sugar chains	Cterm		IgA	P11912		The plant-based S-hyIgA exhibited antigen binding, and was modified with plant-specific N-linked sugar chains.
31178836	1	79	gly	glycoprotein	170:181	arg1	env	env				PUBTATOR		env	155971		Exploring the characteristics of the HIV-1 envelope glycoprotein (env) gene in a natural HIV-1 infected individual, with broadly neutralizing activity, may provide insight into the generation of such broadly neutralizing antibodies and initiate the design of an appropriate immunogen.
31178836	1	79	gly	glycoprotein	170:181	arg1	HIV-1 envelope glycoprotein	HIV-1 envelope glycoprotein				PUBTATOR		HIV-1 envelope glycoprotein	155971		Exploring the characteristics of the HIV-1 envelope glycoprotein (env) gene in a natural HIV-1 infected individual, with broadly neutralizing activity, may provide insight into the generation of such broadly neutralizing antibodies and initiate the design of an appropriate immunogen.
30224358	2	47	gly	factor	459:464	arg1	a single known substrate-the so-called HCF-1PRO repeat	host-cell factor 1			a single known substrate-the so-called HCF-1PRO repeat	PUBTATOR		host-cell factor 1	3054		OGT thereby stably glycosylates serines and threonines of numerous proteins and, via a transient glutamate glycosylation, cleaves a single known substrate-the so-called HCF-1PRO repeat of the transcriptional co-regulator host-cell factor 1 (HCF-1).
29681862	0	50	gly	Synthase	54:61	arg1	Increased O-GlcNAcylation	Endothelial Nitric Oxide Synthase Compromises			Increased O-GlcNAcylation	PUBTATOR		Endothelial Nitric Oxide Synthase Compromises	18127		Increased O-GlcNAcylation of Endothelial Nitric Oxide Synthase Compromises the Anti-contractile Properties of Perivascular Adipose Tissue in Metabolic Syndrome.
33103998	3	36	gly	glycoforms	319:328	arg1	ACE2	ACE2				OGER		ACE2	Q9BYF1		We expressed different glycoforms of the Spike-protein and ACE2 in CRISPR-Cas9 glycoengineered cells, and developed corresponding SARS-CoV-2 pseudovirus.
29237830	6	48	gly	glycosylated	915:926	arg1	differentially glycosylated DG	differentially glycosylated DG				Cterm		DG	1605		Here, we examine LASV receptor candidates in primary human cells and found coexpression of Axl with differentially glycosylated DG.
30158294	11	88	gly	non-glycosylated	1726:1741	arg1	non-glycosylated SERINC5	non-glycosylated SERINC5				PUBTATOR		SERINC5	256987		We conclude that although not required for restrictive-activity or Nef-sensitivity, N-linked glycosylation is important for maintaining the steady-state expression of SERINC5 and that non-glycosylated SERINC5 is likely subjected to a quality-control mechanism that induces its proteasomal degradation.IMPORTANCE SERINC5 is a member of a family of multi-pass transmembrane proteins that inhibit the infectivity of retroviruses including HIV-1.
33177111	8	46	gly	CD55	1151:1154	arg1	The O-glycan profile	CD55			The O-glycan profile	OGER		CD55	P08174		The O-glycan profile of CD55 demonstrated a shift in abundance to nonsialylated core 1 and monosialylated core 2 at the expense of the disialylated core 2 structure after ST3GAL1 silencing.
30127001	2	32	gly	modification	273:284	arg1	serine 435			serine 435	serine 435		SpecificSite			serine 435	A recent structural analysis suggested that a novel O-linked hexose modification on serine 435 of the mammalian NOTCH1 core ligand-binding domain lies at the interface with its ligands.
29793953	6	5	gly	glycosylated	1173:1184	arg1	Tagged NTCP	Tagged NTCP				PUBTATOR		Tagged NTCP	6554		Tagged NTCP introduced to both HepG2 and HepaRG cells was glycosylated, with N5 and N11 being sites of N-linked glycosylation.
31892091	7	8	gly	glycoprotein	1511:1522	arg1	bAGP	bAGP				Cterm		bAGP	497200		Tryptic digests of other glycoproteins (i.e. human apolipoprotein CIII (APO-C3) and bovine alpha-1-acid glycoprotein (bAGP)) were also analyzed, demonstrating the applicability to glycopeptides with different glycan composition and nature.
31892091	7	8	gly	glycoprotein	1511:1522	arg1	bovine alpha-1-acid glycoprotein	bovine alpha-1-acid glycoprotein				PUBTATOR		alpha-1-acid glycoprotein	497200		Tryptic digests of other glycoproteins (i.e. human apolipoprotein CIII (APO-C3) and bovine alpha-1-acid glycoprotein (bAGP)) were also analyzed, demonstrating the applicability to glycopeptides with different glycan composition and nature.
34962767	11	84	gly	glycoproteins	1659:1671	arg1	granulocyte colony-stimulating factor	granulocyte colony-stimulating factor				OGER		granulocyte colony-stimulating factor	P09919		We present the use of IMPa in a one-step O-glycoproteomic workflow for glycoprofiling of the purified glycoproteins granulocyte colony-stimulating factor and receptor-type tyrosine-protein phosphatase C without the need for glycopeptide enrichment.
28364041	5	60	gly	glycoproteins	990:1002	arg1	CD144/VE-cadherin	CD144/VE-cadherin				PUBTATOR		CD144	1003		Using two different galectin-3 affinity purification processes, we extracted four cell membrane glycoproteins, CD146/melanoma cell adhesion molecule (MCAM)/MUC18, CD31/platelet endothelial cell adhesion molecule-1 (PECAM-1), CD144/VE-cadherin, and CD106/Endoglin, from vascular endothelial cells.
28364041	5	60	gly	glycoproteins	990:1002	arg1	CD106/Endoglin	CD106/Endoglin				PUBTATOR		CD106	7412		Using two different galectin-3 affinity purification processes, we extracted four cell membrane glycoproteins, CD146/melanoma cell adhesion molecule (MCAM)/MUC18, CD31/platelet endothelial cell adhesion molecule-1 (PECAM-1), CD144/VE-cadherin, and CD106/Endoglin, from vascular endothelial cells.
28364041	5	60	gly	glycoproteins	990:1002	arg1	CD146/melanoma cell adhesion molecule (MCAM)/MUC18	CD146/melanoma cell adhesion molecule (MCAM)/MUC18				PUBTATOR		CD146/melanoma cell adhesion molecule	4162		Using two different galectin-3 affinity purification processes, we extracted four cell membrane glycoproteins, CD146/melanoma cell adhesion molecule (MCAM)/MUC18, CD31/platelet endothelial cell adhesion molecule-1 (PECAM-1), CD144/VE-cadherin, and CD106/Endoglin, from vascular endothelial cells.
28364041	5	60	gly	glycoproteins	990:1002	arg1	CD31/platelet endothelial cell adhesion molecule-1	CD31/platelet endothelial cell adhesion molecule-1				PUBTATOR		CD31/platelet endothelial cell adhesion molecule-1	5175		Using two different galectin-3 affinity purification processes, we extracted four cell membrane glycoproteins, CD146/melanoma cell adhesion molecule (MCAM)/MUC18, CD31/platelet endothelial cell adhesion molecule-1 (PECAM-1), CD144/VE-cadherin, and CD106/Endoglin, from vascular endothelial cells.
30487280	9	106	gly	envelope-glycoprotein	1774:1794	arg1	envelope-glycoprotein spikes	envelope-glycoprotein spikes				PUBTATOR		envelope-glycoprotein	100616444		In neither study, however, was redirection associated with increased neutralization of heterologous tier 2 viruses.IMPORTANCE Engineered SOSIP trimers mimic envelope-glycoprotein spikes, which stud the surface of HIV-1 particles and mediate viral entry into cells.
33340519	3	36	gly	glycosylated	548:559	arg1	angiotensin-converting enzyme 2	angiotensin-converting enzyme 2				OGER		angiotensin-converting enzyme 2	Q9BYF1		The viral spike glycoprotein (S) of SARS-CoV-2 and the human cellular receptor, angiotensin-converting enzyme 2 (ACE2) are both densely glycosylated.
30368301	2	58	gly	glycoprotein	296:307	arg1	hCG	hCG				OGER		hCG			hCG is a hetero-dimeric glycoprotein, specific to the human pregnancy, consisting of an α and a β subunit, so-called hCGα and hCGβ, respectively.
34404781	6	37	gly	erythropoietin	895:908	arg1	diverse N-glycan profiles	erythropoietin			diverse N-glycan profiles	PUBTATOR		erythropoietin	2056		Using GlyCompare, we study diverse N-glycan profiles from glycoengineered erythropoietin.
29753090	10	40	gly	MUC10	1285:1289	arg1	NeuAcα2-3Galβ1-3GalNAc	MUC10			NeuAcα2-3Galβ1-3GalNAc	PUBTATOR		MUC10	17830		A major O-glycan of MUC10 was determined to be NeuAcα2-3Galβ1-3GalNAc.
29753090	10	40	gly	MUC10	1285:1289	arg1	A major O-glycan	MUC10			A major O-glycan	PUBTATOR		MUC10	17830		A major O-glycan of MUC10 was determined to be NeuAcα2-3Galβ1-3GalNAc.
32915505	0	17	gly	Glycans	40:46	arg1	the SARS-CoV-2 Spike Protein	Spike Protein			Glycans	PUBTATOR		Spike Protein	43740568		Structural Characterization of N-Linked Glycans in the Receptor Binding Domain of the SARS-CoV-2 Spike Protein and their Interactions with Human Lectins.
30221662	8	69	gly	modification	1873:1884	arg1	SNAP29 AND O‑GlcNAc modification	SNAP29			O‑GlcNAc modification	PUBTATOR		SNAP29	O95721		Consistent with the myocardium of diabetic rats, it was also shown in the NRCMs that O‑GlcNAc modification of SNAP29 negatively regulated autophagic flux.
30221662	8	89	gly	SNAP29	1889:1894	arg1	O‑GlcNAc modification	SNAP29			O‑GlcNAc modification	PUBTATOR		SNAP29	O95721		Consistent with the myocardium of diabetic rats, it was also shown in the NRCMs that O‑GlcNAc modification of SNAP29 negatively regulated autophagic flux.
34631661	11	1	gly	sites	2032:2036	arg1	HEK-Spike	HEK			sites	PUBTATOR		HEK	2042		The relatively higher amount of high-mannose abundant sites (N17, N234, N343, N616, N709, N717, N801, and N1134) on HEK-Spike suggests that glycan-shielding may differ among the two constructs.
34631661	11	59	gly	HEK-Spike	2094:2102	arg1	high-mannose abundant sites	HEK			high-mannose abundant sites	PUBTATOR		HEK	2042		The relatively higher amount of high-mannose abundant sites (N17, N234, N343, N616, N709, N717, N801, and N1134) on HEK-Spike suggests that glycan-shielding may differ among the two constructs.
33340519	9	42	gly	glycosylation	1197:1209	arg1	SARS-CoV-2	SARS-CoV-2				OGER		SARS	P49591		We suggest that any role of glycosylation in the pathobiology of SARS-CoV-2 will lie beyond its immediate impact of receptor glycosylation on virus binding.
30659065	11	16	part_of	IgM	1842:1844	arg1	N272	IgM		sites N46, N209, and N272		OGER	SpecificSite	IgM	P01871	sites N46, N209, and N272	IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms.
30659065	11	16	part_of	IgM	1842:1844	arg1	N46	IgM		sites N46, N209, and N272		OGER	SpecificSite	IgM	P01871	sites N46, N209, and N272	IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms.
30659065	11	16	part_of	IgM	1842:1844	arg1	IgM sites	IgM		sites N46, N209, and N272		OGER	SpecificSite	IgM	P01871	sites N46, N209, and N272	IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms.
30659065	11	16	part_of	IgM	1842:1844	arg1	N46	IgM		sites N46, N209, and N272		OGER	SpecificSite	IgM	P01871	sites N46, N209, and N272	IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms.
30659065	11	16	part_of	IgM	1842:1844	arg1	IgM sites	IgM		sites N46, N209, and N272		OGER	SpecificSite	IgM	P01871	sites N46, N209, and N272	IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms.
30659065	11	16	part_of	IgM	1842:1844	arg1	IgM sites	IgM		sites N46, N209, and N272		OGER	SpecificSite	IgM	P01871	sites N46, N209, and N272	IgM sites N46, N209, and N272 displayed mostly complex glycans, whereas sites N279 and N439 displayed higher relative abundances of high-mannose glycoforms.
34192302	8	35	gly	found	1378:1382	arg1	M2BP AND tri-antennary and tetra-antennary N-glycans	M2BP			tri-antennary and tetra-antennary N-glycans	PUBTATOR		M2BP	3959		In F4-IP(+) M2BP, many branched structures, including tri-antennary and tetra-antennary N-glycans, were found.
33554253	5	13	gly	have	802:805	arg1	Nonrecombinant Rb-IgGs AND O-glycans	Nonrecombinant Rb-IgGs			O-glycans	Cterm		IgGs	16059		Nonrecombinant Rb-IgGs have N- and O-glycans, and the presence of O-glycans close to the hinge region of the rRb-IgGs might affect the susceptibility of these antibodies to SrtA cleavage.
33554253	5	13	gly	have	802:805	arg1	Nonrecombinant Rb-IgGs AND N-	Nonrecombinant Rb-IgGs			N-	Cterm		IgGs	16059		Nonrecombinant Rb-IgGs have N- and O-glycans, and the presence of O-glycans close to the hinge region of the rRb-IgGs might affect the susceptibility of these antibodies to SrtA cleavage.
30770249	6	6	gly	RIPK3	1017:1021	arg1	OGT-mediated O-GlcNAcylation	RIPK3			OGT-mediated O-GlcNAcylation	OGER		RIPK3	Q9Y572		Mechanistically, OGT-mediated O-GlcNAcylation of the serine-threonine kinase RIPK3 on threonine 467 (T467) prevented RIPK3-RIPK1 hetero- and RIPK3-RIPK3 homo-interaction and inhibited downstream innate immunity and necroptosis signaling.
34379416	9	76	gly	glycosylation	1363:1375	arg1	yPDI	yPDI				Cterm		yPDI	64714		We find that glycosylation of yPDI facilitates its catalytic site to reach close to this surface recess.
32960038	4	15	gly	isomers	954:960	arg1	ribonuclease B	ribonuclease B			isomers	Cterm		ribonuclease B			The technique enables highly resolved chromatographic separation of over 20 high-mannose glycan isomers in ribonuclease B and a diverse range of hybrid and complex-type sialoglycoforms of fetuin.
36303733	3	72	gly	glycans	561:567	arg1	the virus spike protein	spike protein			glycans	PUBTATOR		spike protein	43740568		Our compilation of the network tool had 26 glycosyltransferase and glucosidase enzymes and could infer the pathway of glycosylation machinery based on glycans in the virus spike protein.
29384693	0	76	gly	glycosylation	18:30	arg1	cyclooxygenase-2	cyclooxygenase-2				PUBTATOR		cyclooxygenase-2	5743		Palmitate induces glycosylation of cyclooxygenase-2 in primary human vascular smooth muscle cells.
28187132	6	29	gly	glycans	1095:1101	arg1	IgA1	IgA1			glycans	PUBTATOR		IgA1	P01876		Moreover, rs13226913 represents a strong cis-eQTL for C1GALT1 that encodes the key enzyme responsible for the transfer of galactose to O-linked glycans on IgA1.
29454068	15	75	gly	receptor	2000:2007	arg1	O-GlcNAcylation	receptor for activated C-kinase 1			O-GlcNAcylation	PUBTATOR		receptor for activated C-kinase 1	10399		LAY SUMMARY: O-GlcNAcylation of ribosomal receptor for activated C-kinase 1 at the amino acid serine122 promotes its stability, ribosome localization and interaction with the protein kinase, PKCβII, thus driving the translation of oncogenes and tumorigenesis of hepatocellular carcinoma.
31019513	9	56	gly	glycosylation	1549:1561	arg1	CD22	CD22				PUBTATOR		CD22	933		We used dual-color super-resolution imaging to investigate the impact of altered glycosylation of CD22 on the nanoscale organization of CD22 and its association with BCR.
34631661	7	0	gly	N-glycosites	1390:1401	arg1	the SARS-CoV-2 S proteins	the SARS-CoV-2 S proteins				PUBTATOR		S proteins	43740568		We identified 21 and 19 out of the 22 predicted N-glycosites of the SARS-CoV-2 S proteins produced in CHO and HEK, respectively.
28302723	11	30	gly	OGT	1993:1995	arg1	the tetratricopeptide repeat domain	OGT			the tetratricopeptide repeat domain	PUBTATOR		OGT	8473		Thus, a single amino acid substitution in the regulatory domain (the tetratricopeptide repeat domain) of OGT, which catalyzes the O-GlcNAc post-translational modification of nuclear and cytosolic proteins, appears causal for XLID.
31800099	5	14	gly	hypoglycosylated	859:874	arg1	Plasma CETP	Plasma CETP				PUBTATOR		Plasma CETP	1071		Plasma CETP was hypoglycosylated and less active in B4GALT1-CDG patients compared to matched controls.
29384693	8	20	gly	glycoform	1307:1315	arg1	COX-2	COX-2				PUBTATOR		COX-2	5743		This response was attenuated by N-linked glycosylation inhibition, suggesting that palmitate impacts expression of the fully activated glycoform of COX-2.
31327656	3	13	gly	glycosylated	410:421	arg1	PD-L1	PD-L1				PUBTATOR		Because PD-L1	29126		Because PD-L1 is heavily glycosylated, we developed a method to resolve this by removing the glycan moieties from cell surface antigens via enzymatic digestion, a process termed sample deglycosylation.
31019513	7	42	gly	residues	1322:1329	arg1	CD22	CD22			residues	PUBTATOR		CD22	933		To this end, we mutated five out of the six N-linked glycosylation residues on CD22 localized closest to the sialic acid binding site.
33073996	8	3	gly	carries	1282:1288	arg1	PD-L1 AND polyLacNAc glycans	PD-L1		the N219 sequon	polyLacNAc glycans	PUBTATOR	SpecificSite	PD-L1	29126	N219 sequon	In conclusion, PD-L1 expressed in the MDA-MB-231 breast cancer cell line carries polyLacNAc glycans mostly at the N219 sequon, which displays the highest variability in occupancy and is most likely to influence the interaction with PD-1.
32544330	2	2	gly	glycosylation	283:295	arg1	Ribonuclease 1	Ribonuclease 1				PUBTATOR		Ribonuclease 1	P07998		Ribonuclease 1 (RNase 1), which is the human homologue of the archetypal enzyme RNase A, undergoes N-linked glycosylation at asparagine residues 34, 76, and 88.
32544330	2	2	gly	glycosylation	283:295	arg1	RNase 1	RNase 1				PUBTATOR		RNase 1	6035		Ribonuclease 1 (RNase 1), which is the human homologue of the archetypal enzyme RNase A, undergoes N-linked glycosylation at asparagine residues 34, 76, and 88.
31913636	4	52	gly	glycoprotein	939:950	arg1	the envelope glycoprotein	the envelope glycoprotein				PUBTATOR		envelope glycoprotein	100616444		Iterative rounds of de-N-glycosylation followed by N-glycanation could be repeated at least three times and were observed for other viral glycoproteins/vaccine antigens, including the envelope glycoprotein (Env) from HIV.
31913636	4	52	gly	glycoprotein	939:950	arg1	Env	Env				PUBTATOR		Env	100616444		Iterative rounds of de-N-glycosylation followed by N-glycanation could be repeated at least three times and were observed for other viral glycoproteins/vaccine antigens, including the envelope glycoprotein (Env) from HIV.
30158294	0	50	gly	N-glycosylated	3:16	arg1	SERINC5	N-Glycosylated Form of SERINC5				PUBTATOR		N-Glycosylated Form of SERINC5	256987		An N-glycosylated form of SERINC5 is specifically incorporated into HIV-1 virions.
31256377	4	3	gly	attached	442:449	arg1	Hyl AND a single galactose unit	Hyl			a single galactose unit	OGER		Hyl	P42679		Then, to the 5-hydroxyl group of Hyl, a single galactose unit can be attached to form galactosyl-Hyl (Gal-Hyl) and further glucose can be added to Gal-Hyl to form glucosylgalactosyl-Hyl (GlcGal-Hyl).
34110173	2	15	gly	glycosylation	295:307	arg1	first-generation erythropoietin	first-generation erythropoietin				PUBTATOR		erythropoietin	2056		This study presents an in-depth analytical strategy for glycosylation of first-generation erythropoietin (epoetin beta), including a developed mass spectrometric workflow for N-glycan analysis, bottom-up mass spectrometric methods for site-specific N-glycosylation, and a LC-MS approach for O-glycan identification.
30762425	5	12	gly	β-catenin	998:1006	arg1	the O-GlcNAcylation	-catenin			the O-GlcNAcylation	PUBTATOR		-catenin	1499		Moreover, the O-GlcNAcylation of β-catenin promoted the proliferation, colony formation, and repressed the induction of apoptosis in HEP-G2 and HuH-7 cells.
34774484	4	54	gly	N-glycosylation	587:601	arg1	Trop2	Trop2				PUBTATOR		Trop2	4070		The current study explored the significance of N-glycosylation of Trop2 by substituting specific N-glycan addition sites by site-directed mutagenesis.
31308178	2	5	gly	receptor	468:475	arg1	sialic acid-capped N-glycans	vascular endothelial growth factor receptor 2			sialic acid-capped N-glycans	PUBTATOR		vascular endothelial growth factor receptor 2	3791		By altering the N-glycosylation machinery in the endoplasmic reticulum and Golgi, proinflammatory cytokines promote the modification of endothelial glycoproteins such as vascular endothelial growth factor receptor 2 (VEGFR2) with sialic acid-capped N-glycans.
31308178	2	40	gly	glycoproteins	411:423	arg1	vascular endothelial growth factor receptor 2	vascular endothelial growth factor receptor 2				PUBTATOR		vascular endothelial growth factor receptor 2	3791		By altering the N-glycosylation machinery in the endoplasmic reticulum and Golgi, proinflammatory cytokines promote the modification of endothelial glycoproteins such as vascular endothelial growth factor receptor 2 (VEGFR2) with sialic acid-capped N-glycans.
29615517	4	1	gly	glycosylation	720:732	arg1	NgR1	NgR1				PUBTATOR		NgR1	65079		Endogenous and overexpressed ORL1 coimmunoprecipitated with immature NgR1 protein, and ORL1 enhanced the O-linked glycosylation and surface expression of NgR1 in HEK293T and Neuro2A cells and primary neurons.
29093093	3	107	gly	S	433:433	arg1	a major determinant	S protein			a major determinant	OGER		S protein	P04004		The S protein is a major determinant of the zoonotic potential of coronaviruses and is also the main target of the host humoral immune response.
31931833	7	25	gly	modification	1414:1425	arg1	the glycosite Asn297			the glycosite Asn297	the glycosite Asn297		AminoAcid			glycosite Asn297	When the Endo-T was expressed in Golgi, the secreted IgG1-Fc region was efficiently produced with almost completely truncated N-glycans and the N-GlcNAc modification on the glycosite Asn297 was confirmed via Mass Spectrometry.
29793953	4	134	gly	unglycosylated	889:902	arg1	Endogenous NTCP protein	Endogenous NTCP protein				PUBTATOR		Endogenous NTCP protein	6554		Endogenous NTCP protein from differentiated HepaRG cells was unglycosylated despite wild-type coding sequence.
31600726	4	73	gly	glycoforms	575:584	arg1	FSH glycoforms	FSH glycoforms				PUBTATOR		FSH	14308		The relative abundance of FSH glycoforms changes with advanced reproductive age, shifting from predominantly FSH21/18 in younger women to FSH24 in older women.
33295603	0	81	gly	O-glycosylation	78:92	arg1	IgA1	IgA1				PUBTATOR		IgA1	P01876		Quantitative assessment of successive carbohydrate additions to the clustered O-glycosylation sites of IgA1 by glycosyltransferases.
32030495	3	35	gly	moieties	917:924	arg1	546 intact N-glycopeptide IDs	IDs			moieties	OGER		IDs	P22304		The N-glycan moieties in 546 intact N-glycopeptide IDs were identified with more than one structure-diagnostic fragment ions where multiple linkage structures exist for each of the monosaccharide compositions.
29530659	6	54	gly	glycosylation	939:951	arg1	HA2	HA2				OGER		HA2			The Assam15 virus had an additional N-linked glycosylation on HA2 (position 557) compared to Kerala14 virus.
32168410	7	80	gly	deglycosylated	892:905	arg1	deglycosylated FXIII-B	deglycosylated FXIII-B				PUBTATOR		FXIII-B	2165		The structure of deglycosylated FXIII-B was investigated by gel filtration.
29769320	3	8	gly	OGT	546:548	arg1	the tetratricopeptide (TPR) repeats	OGT			the tetratricopeptide (TPR) repeats	PUBTATOR		OGT	8473		Three missense mutations in the tetratricopeptide (TPR) repeats of OGT have recently been reported to cause X-linked intellectual disability (XLID).
29769320	3	8	gly	OGT	546:548	arg1	TPR	OGT			TPR	PUBTATOR		OGT	8473		Three missense mutations in the tetratricopeptide (TPR) repeats of OGT have recently been reported to cause X-linked intellectual disability (XLID).
31231989	2	84	gly	SLC35A2	308:314	arg1	a UDP-galactose transporter	SLC35A2			a UDP-galactose transporter	PUBTATOR		SLC35A2	7355		De novo variants in the SLC35A2 gene, which encodes a UDP-galactose transporter, are responsible for CDGs with an X-linked dominant manner.
32171833	3	37	gly	glycosylated	441:452	arg1	GSP	GSP				PUBTATOR		GSP	14683		Their effects on body weight, fasting blood glucose (FBG), glycosylated serum protein (GSP), serum insulin levels (HOMA-IR), blood lipids (including total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c), and high-density lipoprotein cholesterol (HDL-c)) were tested.
33295603	5	100	gly	O-glycans	1017:1025	arg1	IgA1	IgA1			O-glycans	PUBTATOR		IgA1	P01876		Here, we describe a series of nano-liquid chromatography (LC)-mass spectrometry (MS) analyses that demonstrate the range of glycosyltransferase enzymatic activities involved in the biosynthesis of clustered O-glycans on IgA1.
29305779	5	55	gly	moiety	1151:1156	arg1	LW-1	LW-1			moiety	PUBTATOR		LW-1	100506164		Advanced NMR techniques (1H-NMR, 13C-NMR, 1H-13C HSQC, 1H-1H TOCSY, 1H-13C HMBC) together with LC-mass spectrometry (MS) revealed a loss of 176 amu (atomic mass unit) unequivocally point to the presence of a glucuronic acid moiety in LW-1.
33947960	2	25	gly	glycosylation	522:534	arg1	the oncogenic cell surface receptor tyrosine kinase (RTK) ErbB2	the oncogenic cell surface receptor tyrosine kinase (RTK) ErbB2				PUBTATOR		ErbB2	2064		Trastuzumab's target epitope is localized within the extracellular domain of the oncogenic cell surface receptor tyrosine kinase (RTK) ErbB2, which is known to undergo extensive N-linked glycosylation.
29681862	9	84	gly	synthase	1863:1870	arg1	increased O-GlcNAcylation	endothelial nitric oxide synthase			increased O-GlcNAcylation	PUBTATOR		endothelial nitric oxide synthase	24600		PVAT from high sugar diet-fed rats for 12 weeks exhibited decreased NO formation, reduced expression of endothelial nitric oxide synthase (eNOS) and increased O-GlcNAcylation of eNOS.
29681862	9	97	gly	eNOS	1912:1915	arg1	increased O-GlcNAcylation	eNOS			increased O-GlcNAcylation	PUBTATOR		eNOS	24600		PVAT from high sugar diet-fed rats for 12 weeks exhibited decreased NO formation, reduced expression of endothelial nitric oxide synthase (eNOS) and increased O-GlcNAcylation of eNOS.
31186110	0	43	gly	glycosylated	6:17	arg1	Novel glycosylated human interferon alpha 2b	Novel glycosylated human interferon alpha 2b				PUBTATOR		interferon alpha 2b	3440		Novel glycosylated human interferon alpha 2b expressed in glycoengineered Pichia pastoris and its biological activity: N-linked glycoengineering approach.
26040437	4	22	gly	glycosylated	873:884	arg1	the recombinant HA1 proteins	the recombinant HA1 proteins				PUBTATOR		HA1 proteins	23526		Treatment of tunicamycin and peptide-N-glycosidase F (PNGase F) further revealed that the recombinant HA1 proteins produced in insect cells were indeed glycosylated with N-linked oligosaccharide side chains.
31133022	8	36	gly	structures	1631:1640	arg1	GPI-APs	APs			structures	OGER		APs	P07288		Furthermore, specific binding of the lectin module with biantennary bisialylated nonfucosylated N-glycan or sialyl Lewis X-containing glycan structures on GPI-APs triggers substantial conformational changes in the aerolysin module, which interacts with SM, ultimately resulting in the formation of a membrane-bound oligomer in lipid rafts.
31133022	8	72	gly	N-glycan	1586:1593	arg1	GPI-APs	APs			N-glycan	OGER		APs	P07288		Furthermore, specific binding of the lectin module with biantennary bisialylated nonfucosylated N-glycan or sialyl Lewis X-containing glycan structures on GPI-APs triggers substantial conformational changes in the aerolysin module, which interacts with SM, ultimately resulting in the formation of a membrane-bound oligomer in lipid rafts.
30422384	6	47	gly	glycosylation	1053:1065	arg1	human proMMP-9	human proMMP-9				OGER		MMP-9			Moreover, we investigated the effect of glycosylation on proteolytic activation of human proMMP-9 with the use of zymography and dye-quenched gelatin cleavage analysis.
31527085	6	31	gly	site	775:778	arg1	sOGT	sOGT			site	Cterm		sOGT	8473		Here, we performed LC-MS/MS and mutational analyses to seek the major O-GlcNAcylation site on sOGT.
29321565	8	36	gly	B	1543:1543	arg1	the high-mannose-containing oligosaccharides residues	RNase B			the high-mannose-containing oligosaccharides residues	OGER		RNase B	P07998		Recombinant ORF1188, Beauveria and Cordyceps ENGases released the fucose-containing oligosaccharides residues from rituximab (immunoglobulin G) but not the high-mannose-containing oligosaccharides residues from RNase B, a result that not only confirmed the substrate specificity of these novel ENGases but also suggested that natural glycoproteins could be their substrates.
31527367	9	82	gly	glycosylation	1397:1409	arg1	Cav3.2	Cav3.2				PUBTATOR		Cav3.2	8912		It is known that increased extracellular glucose levels enhance Cav3.2 activity through asparagine (N)-linked glycosylation of Cav3.2, which might contribute to diabetic neuropathy.
30217067	4	75	gly	transferase	722:732	arg1	glucose transporters	O-linked β-N-acetlyglucosamine transferase			glucose transporters	PUBTATOR		O-linked β-N-acetlyglucosamine transferase	8473		To identify the potential mechanism, we assessed the expression of O-linked β-N-acetlyglucosamine transferase (OGT) and glycoside hydrolase O-GlcNAcase (OGA), as well as hypoxia-inducible factor 1-alpha (HIF1A) and glucose transporters (GLUT1, GLUT3).
30305605	7	61	gly	O-glycosylated	1145:1158	arg1	differentially O-glycosylated Cel	differentially O-glycosylated Cel				PUBTATOR		Cel	12613		Here, we provide data suggesting that differentially O-glycosylated Cel could negatively affect beta cell function.
29339411	3	66	gly	O-glycosylated	671:684	arg1	a diversely and heavily O-glycosylated flagellin C9LY14	a diversely and heavily O-glycosylated flagellin C9LY14				Cterm		C9LY14			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29339411	3	82	gly	carries	738:744	arg1	a diversely and heavily O-glycosylated flagellin C9LY14 AND hitherto undescribed rhamnose-	a diversely and heavily O-glycosylated flagellin C9LY14			hitherto undescribed rhamnose-	Cterm		C9LY14			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29339411	3	82	gly	carries	738:744	arg1	a diversely and heavily O-glycosylated flagellin C9LY14 AND N-acetylglucosamine linked O-glycans	a diversely and heavily O-glycosylated flagellin C9LY14			N-acetylglucosamine linked O-glycans	Cterm		C9LY14			Here we provide the first report of a Selenomonas glycoprotein, showing that S. sputigena produces a diversely and heavily O-glycosylated flagellin C9LY14 as a major cellular protein, which carries various hitherto undescribed rhamnose- and N-acetylglucosamine linked O-glycans in the range from mono- to hexasaccharides.
29672582	0	57	gly	IgG4	24:27	arg1	N-glycans	IgG4			N-glycans	OGER		IgG4	P01861		Changes in N-glycans of IgG4 and its relationship with the existence of hypocomplementemia and individual organ involvement in patients with IgG4-related disease.
28700571	2	34	gly	glycoprotein	314:325	arg1	Env	Env				Cterm		Env			The envelope glycoprotein (Env) trimer on the surface of HIV is responsible for receptor binding and fusion.
31616924	0	86	gly	O-glycosylation	0:14	arg1	plasma apolipoprotein E	plasma apolipoprotein E				PUBTATOR		apolipoprotein E	348		O-glycosylation on cerebrospinal fluid and plasma apolipoprotein E differs in the lipid-binding domain.
30364948	2	30	gly	di-glycosylated	333:347	arg1	Glycocin F	Glycocin F				Cterm		Glycocin F (GccF			Glycocin F (GccF) is an unusually di-glycosylated bacteriocin produced in a lactic acid bacterium, Lactobacillus plantarum KW30 that has been shown to be resistant to extreme conditions.
32109505	3	75	gly	N-glycosylated	390:403	arg1	TRPM8	TRPM8				PUBTATOR		TRPM8	79054		TRPM8 is N-glycosylated, with a single site per subunit.
34192331	5	66	gly	IgGs	782:785	arg1	tri-antennary complex-type N-glycans	However, IgGs			tri-antennary complex-type N-glycans	Cterm		However, IgGs			However, IgGs with tri-antennary complex-type N-glycans have been generated using the N-glycan remodeling technique, suggesting that more branched N-glycans might be artificially attached.
31489629	5	12	gly	phosphoglycoprotein	905:923	arg1	matrix extracellular phosphoglycoprotein	matrix extracellular phosphoglycoprotein				OGER		matrix extracellular phosphoglycoprotein	Q9ES02		The gene and protein expressions of noncollagen proteins (BSP, bone sialoprotein; OCN, osteocalcin; OPN, osteopontin), p38 mitogen-activated protein kinase, and SIBLINGs (Small Integrin-Binding LIgand N-linked Glycoproteins) members (DMP1, dentine matrix protein 1, DSPP, dentin sialophosphoprotein, and MEPE, matrix extracellular phosphoglycoprotein) were detected by reverse-transcription quantitative polymerase chain reaction and western blot analysis.
34278967	7	69	gly	trimer	1401:1406	arg1	N-glycan profile	S trimer			N-glycan profile	Cterm		S trimer	43740568		Using structural information and determined N-glycan profile of S trimer, taking together with the carbohydrate specificity of lentil lectin, we provide a basis for the observed broad spectrum anti-SARS-CoV-2 activity.
31665542	4	9	gly	glycoprotein	664:675	arg1	the S-layer protein Mpsy_1486	the S-layer protein Mpsy_1486				Cterm		Mpsy_1486			Lectin affinity enriched a glycoprotein in cells grown at 30 °C under ample substrate availability, which was identified as the S-layer protein Mpsy_1486.
32258897	0	48	gly	Heterogeneity	14:26	arg1	rhIFN-β	rhIFN-β				Cterm		rhIFN-β	3456		Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β).
32258897	0	48	gly	Heterogeneity	14:26	arg1	Hyperglycosylated Recombinant Human Interferon-β	Hyperglycosylated Recombinant Human Interferon-β				PUBTATOR		Human Interferon-β 	3456		Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β).
32258897	0	57	gly	Hyperglycosylated	31:47	arg1	rhIFN-β	rhIFN-β				Cterm		rhIFN-β	3456		Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β).
32258897	0	57	gly	Hyperglycosylated	31:47	arg1	Hyperglycosylated Recombinant Human Interferon-β	Hyperglycosylated Recombinant Human Interferon-β				PUBTATOR		Human Interferon-β 	3456		Glycosylation Heterogeneity of Hyperglycosylated Recombinant Human Interferon-β (rhIFN-β).
33167210	3	16	gly	glycosylation	519:531	arg1	PSA	PSA				PUBTATOR		PSA	354		To understand the involvement of PSA glycosylation in the fertilization process, analytical methods are required to study the glycosylation of PSA from seminal plasma with a high glycoform resolution and in a protein-specific manner.
30487799	5	23	gly	observed	873:880	arg2	tetrameric IgM AND no glycan occupancy	tetrameric IgM			no glycan occupancy	PUBTATOR		IgM	P01871		A striking decrease in the level of occupancy at the Asn-565 glycosite was observed in dimeric IgM compared to that in monomeric IgM, and no glycan occupancy of Asn-565 was observed in tetrameric IgM.
29755357	6	33	gly	non-glycosylated	1066:1081	arg1	the non-glycosylated LCN2 variants	the non-glycosylated LCN2 variants				PUBTATOR		LCN2 variants	3934		Moreover, both the glycosylated and the non-glycosylated LCN2 variants are equally targeted to exosomes, demonstrating that this post-translational modification is not necessary for proper trafficking of LCN2 into these membranous extracellular vesicles.
29530619	0	73	gly	Nav1.5	27:32	arg1	O-GlcNAcylation	Nav1.5			O-GlcNAcylation	PUBTATOR		Nav1.5	25665		O-GlcNAcylation of cardiac Nav1.5 contributes to the development of arrhythmias in diabetic hearts.
31300553	4	47	gly	eIF4G1	868:873	arg1	the O-GlcNAcylation	eIF4G1			the O-GlcNAcylation	PUBTATOR		eIF4G1	208643		Here, using several approaches, including site-directed mutagenesis, Click O-GlcNAc labeling, immunoblotting, and immunofluorescence and EM imaging, we provide the first evidence for a relationship between the O-GlcNAcylation of eukaryotic translation initiation factor 4γ1 (eIF4G1) and carboxypeptidase E (CPE)-dependent proinsulin processing in βOGTKO mice.
29237830	13	40	gly	LASV	2031:2034	arg1	dystroglycan	LASV			dystroglycan	Cterm		LASV			Although the principal LASV receptor, dystroglycan (DG), is ubiquitously expressed, virus binding critically depends on DG's posttranslational modification, which does not always correlate with tissue tropism.
31604106	16	41	gly	O-glycosylation	2799:2813	arg1	recombinant hCG protein	recombinant hCG protein				PUBTATOR		hCG protein	93659		This study revealed the major limiting factors of O-glycosylation of recombinant hCG protein in CHO cells and proposed an effective expression regulation strategy.
26040437	2	96	gly	glycosylation	333:345	arg1	the HA1 proteins	the HA1 proteins				PUBTATOR		HA1 proteins	23526		Biosynthesis, glycosylation and secretion of the HA1 proteins, with natural or a melittin signal peptide at the N-terminus and a six-histidine (6xHis) tag at the C-terminus, were examined in insect cells.
31831633	2	37	gly	glycosylated	400:411	arg1	this abnormally glycosylated MUC1	this abnormally glycosylated MUC1				OGER		MUC1	P15941		Changes in glycosylation of the oncoprotein MUC1 commonly occur in chronic inflammation, including ulcerative colitis, and this abnormally glycosylated MUC1 promotes cancer development and progression.
31831633	2	62	gly	glycosylation	272:284	arg1	the oncoprotein MUC1	the oncoprotein MUC1				OGER		MUC1	P15941		Changes in glycosylation of the oncoprotein MUC1 commonly occur in chronic inflammation, including ulcerative colitis, and this abnormally glycosylated MUC1 promotes cancer development and progression.
31604106	11	12	gly	polypeptide	1857:1867	arg1	Galnt1	polypeptide N-acetylgalactosaminyltransferase1			Galnt1	PUBTATOR		polypeptide N-acetylgalactosaminyltransferase1	2589		Furthermore, the effects and mechanisms of the key genes of O-glycan sugar chain synthesis and hydrolases such as polypeptide N-acetylgalactosaminyltransferase1 (Galnt1), Core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase (C1galt1), O-linked N-acetylglucosamine transferase (Ogt) and Hexosaminidase (Hex), were evaluated.
29793953	8	123	gly	nonglycosylated	1482:1496	arg1	nonglycosylated NTCP	nonglycosylated NTCP				PUBTATOR		NTCP	6554		In conclusion, nonglycosylated NTCP is expressed by differentiated HepaRG cells and capable of mediating cHBV infection in HepG2 cells, but it cannot explain differential susceptibility of HepaRG and HepG2/NTCP cells to cHBV versus sHBV infection and different HBsAg/HBeAg ratios following cHBV infection.
33273015	10	68	gly	carrying	1762:1769	arg1	nMPO AND hyper-truncated glycans	nMPO			hyper-truncated glycans	Cterm		nMPO	P05164		Enzymatic trimming of the Asn355-/Asn391-glycans recapitulated the activity gain and showed that nMPO carrying hyper-truncated glycans at these positions exhibits increased thermal stability, polypeptide accessibility and ceruloplasmin-mediated inhibition potential relative to native nMPO.
31029427	9	11	gly	site	1502:1505	arg1	FOXA1	FOXA1			site	PUBTATOR		FOXA1	3169		Additionally, we performed ESI-ETD-MS/MS analysis of the full-length O-GalNAcylated FOXA1 protein and identified S355 as the O-GalNAc modification site on FOXA1, consistent with the peptide reaction.
33347638	3	117	gly	PSA	492:494	arg1	the disadvantage	PSA			the disadvantage	OGER		PSA	P07288		The aim of this study was to develop a better resolution for diagnosing prostate cancer to overcome the disadvantage of PSA.
30044221	5	15	gly	glycosylation	929:941	arg1	the α1 subunit	the α1 subunit				PUBTATOR		1 subunit	146		Remarkable N-linked glycosylation on the α1 subunit occludes the extracellular vestibule of the ion channel and is poised to modulate receptor assembly and perhaps ion channel gating.
30231545	6	3	gly	AKT	953:955	arg1	the glucose metabolism regulators	AKT			the glucose metabolism regulators	PUBTATOR		AKT	11651		This was accompanied by significantly increased activation levels of the glucose metabolism regulators 160 kDa AKT substrate (AS160), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2), and glycogen synthase kinase-3β (GSK3β).
30231545	6	6	gly	glycogen	1044:1051	arg1	the glucose metabolism regulators	glycogen synthase kinase-3β 			the glucose metabolism regulators	PUBTATOR		glycogen synthase kinase-3β 	56637		This was accompanied by significantly increased activation levels of the glucose metabolism regulators 160 kDa AKT substrate (AS160), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2), and glycogen synthase kinase-3β (GSK3β).
31094416	2	30	gly	CD146	504:508	arg1	15N-labeled Gal-3	CD146			15N-labeled Gal-3	PUBTATOR		CD146	4162		Here, we used Nuclear Magnetic Resonance (NMR) 15N-Heteronuclear Single Quantum Coherence (HSQC) spectroscopy to investigate binding between 15N-labeled Gal-3 and the extracellular domain (eFL) of purified CD146 (five Ig-like ectodomains D1-D5) and a shorter, D5-deleted version of CD146 (D1-D4).
29263266	2	57	gly	lectin	393:398	arg1	GalNAc-binding affinity	lectin			GalNAc-binding affinity	PUBTATOR		lectin	547726		Here, we demonstrate that a soybean-derived lectin (SBL) with GalNAc-binding affinity could potently suppress HIV infection of macrophages in a dose-dependent fashion.
34770808	4	6	gly	linked	679:684	arg2	hIgG AND these complex oligosaccharides	hIgG			these complex oligosaccharides	Cterm		IgG			To achieve the profile information of these complex oligosaccharides, linked by asparagine to hIgG in the blood, the glycoproteins of the samples needed to be cleaved, labelled, and purified with sufficient yield and selectivity.
31831633	5	93	gly	glycoforms	818:827	arg1	aberrant MUC1 glycoforms	aberrant MUC1 glycoforms				OGER		MUC1	P15941		We analyzed the involvement of macrophage-associated cytokines in the induction of aberrant MUC1 glycoforms.
32172531	1	17	gly	glycosylation	188:200	arg1	The human ether-a-go-go related gene (hERG)-encoded channel hERG	The human ether-a-go-go related gene (hERG)-encoded channel hERG				PUBTATOR		hERG	2078		The human ether-a-go-go related gene (hERG)-encoded channel hERG undergoes N-linked glycosylation at position 598, which is located in the unusually long S5-pore linker of the channel.
28186505	0	26	gly	N-glycosylation	0:14	arg1	mouse TRAIL-R	mouse TRAIL-R				PUBTATOR		TRAIL	22035		N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.
28186505	0	26	gly	N-glycosylation	0:14	arg1	human TRAIL-R1	human TRAIL-R1				PUBTATOR		TRAIL-R1	8797		N-glycosylation of mouse TRAIL-R and human TRAIL-R1 enhances TRAIL-induced death.
31336868	7	2	gly	β-glucosidase	2297:2309	arg1	L-ido-azepane	-glucosidase			L-ido-azepane	PUBTATOR		-glucosidase	6476		Furthermore, besides α-glucosidase inhibition, both miglitol (41a) and L-ido-azepane (41b) proved to be the strongest β-glucosidase inhibitors of the series with IC50 of 4 µM.
31527085	5	65	gly	sites	643:647	arg1	sOGT	sOGT			sites	Cterm		sOGT	8473		To date, the major O-GlcNAcylation sites and their roles in sOGT remain unknown.
30514763	0	39	gly	O-glycosylation	40:54	arg1	the adhesin MIC2	the adhesin MIC2				OGER		MIC2	P14209		Protein O-fucosyltransferase 2-mediated O-glycosylation of the adhesin MIC2 is dispensable for Toxoplasma gondii tachyzoite infection.
32544330	4	43	gly	glycan	567:572	arg1	Asn34			Asn34	Asn34		AminoAcid			Asn34	The glycan on Asn34 is relatively compact and rigid, donates hydrogen bonds that "cap" the carbonyl groups at the C-terminus of an α-helix, and enhances protein thermostability.
31341641	1	4	part_of	gp120	252:256	arg1	V1-V5	gp120		V1-V5		PUBTATOR	SiteSequence	gp120	155971	V1-V5	The transmission fitness and pathogenesis of HIV-1 is disproportionately influenced by evolution in the five variable regions (V1-V5) of the surface envelope glycoprotein (gp120).
28528272	1	9	gly	glycosylated	218:229	arg1	The asparaginyl endopeptidase legumain and its inhibitor cystatin E/M	The asparaginyl endopeptidase legumain and its inhibitor cystatin E/M				OGER		asparaginyl endopeptidase legumain	Q99538		The asparaginyl endopeptidase legumain and its inhibitor cystatin E/M are endogenously glycosylated.
35140700	0	51	gly	Glycosylation	52:64	arg1	IgG	IgG				Cterm		IgG			Cytokines in the Immune Microenvironment Change the Glycosylation of IgG by Regulating Intracellular Glycosyltransferases.
33340519	5	9	gly	glycoforms	730:739	arg1	engineered ACE2 glycoforms	engineered ACE2 glycoforms				OGER		ACE2	Q9BYF1		We generated a panel of engineered ACE2 glycoforms which were analyzed by mass spectrometry to reveal the site-specific glycan modifications.
28931878	3	18	gly	N-glycans	446:454	arg1	IgGs	IgGs			N-glycans	Cterm		IgGs			We discover 20 sulfated and 4 acetylated N-glycans on IgGs.
33073996	2	52	gly	N-glycosylation	211:225	arg1	PD-L1	PD-L1				PUBTATOR		PD-L1	29126		N-glycosylation of PD-L1 affects its interaction with PD-1, but little is known about the distribution of glycoforms at its four NXS/T sequons.
29997173	1	15	gly	glycoprotein	171:182	arg1	CD52	CD52				OGER		CD52	P31358		CD52, a glycophosphatidylinositol (GPI)-anchored glycoprotein, is released in a soluble form following T cell activation and binds to the Siglec (sialic acid-binding Ig-like lectin)-10 receptor on T cells to suppress their function.
30633504	4	40	gly	monoglycosylated	779:794	arg1	RNase 1	RNase 1				PUBTATOR		RNase 1	6035		As a glutamine residue is not a substrate for cellular oligosaccharyltransferase, we used strategic asparagine-to-glutamine substitutions to produce the three diglycosylated and three monoglycosylated forms of RNase 1.
30633504	4	55	gly	diglycosylated	754:767	arg1	RNase 1	RNase 1				PUBTATOR		RNase 1	6035		As a glutamine residue is not a substrate for cellular oligosaccharyltransferase, we used strategic asparagine-to-glutamine substitutions to produce the three diglycosylated and three monoglycosylated forms of RNase 1.
30250045	1	60	gly	sialylated	189:198	arg1	the sialylated protein HEG homolog 1	the sialylated protein HEG homolog 1				PUBTATOR		HEG homolog 1	57493		The anti-mesothelioma mAb SKM9-2 recognizes the sialylated protein HEG homolog 1 (HEG1).
30250045	1	60	gly	sialylated	189:198	arg1	HEG1	HEG1				PUBTATOR		HEG1	Q9ULI3		The anti-mesothelioma mAb SKM9-2 recognizes the sialylated protein HEG homolog 1 (HEG1).
31600726	7	86	gly	glycoforms	1095:1104	arg1	purified recombinant FSH glycoforms	purified recombinant FSH glycoforms				PUBTATOR		FSH	14308		In this study, we isolated secondary follicles from pre-pubertal mice and treated them with 20- or 100 ng/mL purified recombinant FSH glycoforms for 1 h or 18-20 h. Analysis of phosphorylated PKA substrates showed that glycoforms were bioactive in follicles following 1-h treatment, although differential bioactivity was only observed with the 100 ng/mL dose.
34192302	11	23	gly	found	1617:1621	arg2	serum M2BP AND The LacdiNAc structure	serum M2BP			The LacdiNAc structure	PUBTATOR		M2BP	3959		The LacdiNAc structure was not found in serum M2BP.
31471298	7	5	gly	glycans	1218:1224	arg1	ACPA-IgG	ACPA			glycans	PUBTATOR		ACPA	5657		RESULTS V-domain glycans on ACPA-IgG were already present up to 15 years before disease in pre-symptomatic individuals and their abundance increased closer to symptom onset.
34662441	8	77	gly	glycoforms	1647:1656	arg1	PSMA	PSMA				OGER		PSMA	Q04609		CONCLUSIONS Our study presents initial descriptive analysis of the glycoforms of PSMA observed in cell lines and in prostate tissue.
30479582	2	4	gly	glycosylation	433:445	arg1	recombinant IgG	recombinant IgG				Cterm		IgG			This task is essential in the biotherapeutics industry, where the type and amount of glycosylation on recombinant IgG alter the efficacy, function, and immunogenicity.
31308178	3	61	gly	N-glycosylated	542:555	arg1	VEGFR2	VEGFR2				PUBTATOR		VEGFR2	3791		VEGFR2 is a highly N-glycosylated receptor tyrosine kinase involved in pro-angiogenic signaling in physiological and pathological contexts, including cancer.
31722217	2	61	gly	has	336:338	arg1	Notch AND 22 O-fucosylation sites	Notch			22 O-fucosylation sites	PUBTATOR		Notch	31293		Although Notch has 22 O-fucosylation sites, the biologically relevant sites affecting Notch activity during animal development in vivo in the presence or absence of Fringe are not known.
29030255	9	84	part_of	present	1229:1235	arg2	pufferfish CA VI AND Cys-209	CA VI		Cys-28 and Cys-209		PUBTATOR	SpecificSite	CA VI	765	Cys-28 and Cys-209	Three potential N-linked glycosylation sites and two cysteine residues (Cys-28 and Cys-209) that are likely to form one disulfide bond were present in pufferfish CA VI.
33177111	9	34	gly	CD55	1369:1372	arg1	O-linked desialylation	CD55			O-linked desialylation	OGER		CD55	P08174		We also demonstrated that O-linked desialylation of CD55 by ST3GAL1 silencing resulted in increased C3 deposition and complement-mediated lysis of breast cancer cells and enhanced sensitivity to antibody-dependent cell-mediated cytotoxicity.
33177111	9	72	gly	desialylation	1352:1364	arg1	CD55	CD55				OGER		CD55	P08174		We also demonstrated that O-linked desialylation of CD55 by ST3GAL1 silencing resulted in increased C3 deposition and complement-mediated lysis of breast cancer cells and enhanced sensitivity to antibody-dependent cell-mediated cytotoxicity.
29755357	8	17	gly	N-glycosylation	1473:1487	arg1	LCN2	LCN2				PUBTATOR		LCN2	3934		In sum, our data indicate that the N-glycosylation of LCN2 is not required for proper secretion and exosome cargo recruitment in different cell types, but might be relevant to increase overall solubility.
34229070	0	42	gly	O-glycosylation	26:40	arg1	APP	APP				OGER		APP	P05067		Comprehensive analysis of O-glycosylation of amyloid precursor protein (APP) using targeted and multi-fragmentation MS strategy.
34229070	0	42	gly	O-glycosylation	26:40	arg1	amyloid precursor protein	amyloid precursor protein				PUBTATOR		amyloid precursor protein	351		Comprehensive analysis of O-glycosylation of amyloid precursor protein (APP) using targeted and multi-fragmentation MS strategy.
32764711	0	69	gly	glycoprotein	50:61	arg1	envelope glycoprotein	envelope glycoprotein				PUBTATOR		envelope glycoprotein	64006		Comprehensive N-glycosylation mapping of envelope glycoprotein from tick-borne encephalitis virus grown in human and tick cells.
30348809	11	61	gly	glycosylation	1423:1435	arg1	CSF3R	CSF3R				OGER		CSF3R	Q99062		SIGNIFICANCE: This study reveals the critical importance of membrane-proximal N-linked glycosylation of CSF3R for the maintenance of ligand dependency in leukemia.
33577335	3	1	gly	glycosylated	470:481	arg1	IL-17A	IL-17A				PUBTATOR		IL-17A	3605		Here we report our synthesis and evaluation of homogeneously glycosylated interleukin-17A (IL-17A), based on a synthetic approach combining solid-phase synthesis of (glyco)peptides, chemoenzymatic glycan modification on segments, and chemical ligations.
33577335	3	1	gly	glycosylated	470:481	arg1	homogeneously glycosylated interleukin-17A	homogeneously glycosylated interleukin-17A				PUBTATOR		interleukin-17A	3605		Here we report our synthesis and evaluation of homogeneously glycosylated interleukin-17A (IL-17A), based on a synthetic approach combining solid-phase synthesis of (glyco)peptides, chemoenzymatic glycan modification on segments, and chemical ligations.
32035902	2	36	gly	N-glycosylation	224:238	arg1	ECD	ECD				OGER		ECD	O95905		N-glycosylation of asparagine 130 in its extracellular domain (ECD) enhances calcitonin hormone affinity with the proximal GlcNAc residue mediating this effect through an unknown mechanism.
33947960	3	59	gly	ErbB2	585:589	arg1	the site-specific glycan repertoire	ErbB2			the site-specific glycan repertoire	PUBTATOR		ErbB2	2064		However, the site-specific glycan repertoire of ErbB2, as well as the detailed molecular mechanisms through which specific aberrant glycan signatures functionally impact the malignant features of ErbB2-addicted GC cells, including the acquisition of trastuzumab resistance, remain elusive.
34278967	2	41	gly	glycosylated	329:340	arg1	S protein	S protein				PUBTATOR		S protein	Q15517		S protein is heavily glycosylated and the glycosylation sites are relatively conserved, thus glycans on S protein surface could be a target for the development of anti-SARS-CoV-2 strategies against variants.
29246839	5	56	gly	glycoprotein	1002:1013	arg1	Sa1-SSTrec	Sa1-SSTrec				OGER		Sa1	Q8WVM7		Sa1-SSTrec purified from the culture supernatant was a monomeric glycoprotein optimally active at pH 5.0-6.0 and 45-50 °C.
31826991	14	56	gly	have	2317:2320	arg1	H3 HAs AND one or more key high-mannose glycosites	H3 HAs			one or more key high-mannose glycosites	OGER		H3 HAs	Q92839		While it is known that both H1 and H3 HAs have one or more key high-mannose glycosites in the head region, little is known about similar glycosylation of LPAIV strains H2N1, H5N1, H6N1, or H11N9, which may pose future health risks.
32172531	9	42	gly	glycosylation	1392:1404	arg1	hERG channel stability	hERG channel				PUBTATOR		hERG channel	2078		In summary, our results revealed that N-linked glycosylation protects hERG against protease-mediated degradation and thus contributes to hERG channel stability on the plasma membrane.
34670086	10	0	gly	glycosylation	1688:1700	arg1	the spike protein	the spike protein				PUBTATOR		spike protein	43740568		Overall, we show that in matched expression systems the quaternary protein architecture limits O-linked glycosylation of the spike protein.
30919021	6	19	gly	glycans	713:719	arg1	P4HA1	P4HA1			glycans	PUBTATOR		P4HA1	18451		Downregulation of Stt3b and Magt1 reduces N259 glycans on P4HA1.
30619255	12	4	gly	glycoforms	2443:2452	arg1	distinct O-glycosylation states/CD45 glycoforms	distinct O-glycosylation states/CD45 glycoforms				PUBTATOR		CD45	5788		Thus, our data suggest that O-glycan remodeling is a feature of B cell differentiation, dually regulated by ST3Gal1 and GCNT1, that ultimately results in expression of distinct O-glycosylation states/CD45 glycoforms at each stage of B cell differentiation.
30150325	7	16	gly	group	958:962	arg1	Ser947			Ser947	Ser947		AminoAcid			Ser947	SEC transfers an O-GlcNAc group on Ser947 of ATX1, which resides in the SET domain, thereby activating ATX1.
30054538	11	31	gly	desialylated	1950:1961	arg1	partially desialylated PrPSc	partially desialylated PrPSc				PUBTATOR		PrPSc	19122		Moreover, transient degradation of Iκβα observed upon treatment with partially desialylated PrPSc suggests that canonical NFκB activation pathway is involved in inflammatory response.
31471298	8	42	gly	glycans	1493:1499	arg1	ACPA-IgG	ACPA			glycans	PUBTATOR		ACPA	5657		Noteworthy, human leucocyte antigen class II shared epitope (HLA-SE) alleles associated with the presence of V-domain glycans on ACPA-IgG.
30517873	3	12	part_of	site	558:561	arg1	ULK1	ULK1		site		PUBTATOR	SpecificSite	ULK1	8408	threonine 754 site	Here, we provide evidence that ULK1 is the attachment of O-linked N-acetylglucosamine (O-GlcNAcylated) on the threonine 754 site by O-linked N-acetylglucosamine transferase (OGT) upon glucose starvation.
33826885	3	54	gly	glycosylation	476:488	arg1	native BG505 Env	native BG505 Env				PUBTATOR		BG505 Env	100616444		To eliminate glycan holes and mimic the glycosylation of native BG505 Env, we replace all 12 NxS sequons on BG505 SOSIP with NxT.
28031460	4	8	gly	β-galactoside	630:642	arg1	St6gal1	-galactoside α2,6-sialyltransferase-1			St6gal1	PUBTATOR		-galactoside α2,6-sialyltransferase-1	20440		We found that a gene encoding β-galactoside α2,6-sialyltransferase-1 (St6gal1), a key enzyme responsible for the biosynthesis of α2,6-linked sialic acid in N-linked glycans, was most down-regulated in VATs from obese mice.
36303733	9	69	gly	protein	1598:1604	arg1	the N-glycan profile	S) protein			the N-glycan profile	OGER		S) protein	P04004		Heterogeneity in the N-glycan profile of the spike (S) protein and its potential effect on vaccine efficacy or adverse reactions to the vaccines remain unexplored.
30740857	16	51	gly	glycans	2120:2126	arg1	FVIII	FVIII			glycans	PUBTATOR		FVIII	P00451		Conclusions These findings suggest that CLEC4M is a novel clearance receptor that interacts with mannose-exposed glycans on FVIII in the presence or absence of VWF.
29263266	3	70	gly	glycosylated	578:589	arg1	gp41	gp41				Cterm		gp41			Unlike the MBLs, which block HIV only through binding to the glycosylated envelope proteins (gp120 and gp41) of the virus, SBL inhibited HIV at multiple steps of the virus infection/replication cycle.
29263266	3	70	gly	glycosylated	578:589	arg1	gp120	gp120				OGER		gp120	Q14624		Unlike the MBLs, which block HIV only through binding to the glycosylated envelope proteins (gp120 and gp41) of the virus, SBL inhibited HIV at multiple steps of the virus infection/replication cycle.
33347638	10	87	gly	O-glycosylated	1959:1972	arg1	O-glycosylated clusterin	O-glycosylated clusterin				PUBTATOR		clusterin	1191		Following this discovery, we constructed a Luminex-based assay to quantify O-glycosylated clusterin, in which total serum clusterin was first captured on anti-clusterin antibody-immobilized beads, and then clusterin-associated O-glycans were determined by the pair of biotin-MPA and streptavidin-phycoerythrin.
32663509	8	65	gly	UDP-GlcNAc	1701:1710	arg1	the form	form of B3GNT2			UDP-GlcNAc	PUBTATOR		form of B3GNT2	Q9NY97		The presence of a sink for UDP-GlcNAc in the form of B3GNT2 with no disposition may have also elevated the intracellular levels of this nucleotide as well as its downstream product, CMP-Neu5Ac.
30633504	3	62	gly	triglycosylated	556:570	arg1	human RNase 1	human RNase 1				PUBTATOR		RNase 1	6035		By using an engineered strain of the yeast Pichia pastoris, we installed a heptasaccharide (Man5GlcNAc2) on the side chain of Asn34, Asn76, and Asn88 to produce the authentic triglycosylated form of human RNase 1.
30205382	7	27	gly	p727STAT3	1251:1259	arg1	p727STAT3 expression	STAT3			p727STAT3 expression	PUBTATOR		STAT3	6774		While O-GlcNAcylation inhibited p727STAT3 expression, augmented O-GlcNAcylation could balance p705STAT3 expression within relatively high levels corresponding to vascular endothelial growth factor (VEGF) changes.
28303575	10	7	gly	n-glycosylation	1220:1234	arg1	Dectin-1	Dectin-1				PUBTATOR		Dectin-1	Q9BXN2		We show here that n-glycosylation of Dectin-1 is crucial for its cell surface expression and consequently signal transduction.
32168410	13	11	gly	attached	1591:1598	arg2	FXIII-B AND the glycan moieties	FXIII-B			the glycan moieties	PUBTATOR		FXIII-B	2165		CONCLUSION Characterization of the glycan moieties attached to FXIII-B is reported for the first time.
30514763	3	23	gly	has	582:584	arg1	MIC2 AND highly glycosylated thrombospondin repeat (TSR) domains	MIC2			highly glycosylated thrombospondin repeat (TSR) domains	OGER		2 (MIC2	P14209		Here we demonstrate that micronemal protein 2 (MIC2), a motility-associated adhesin of T. gondii, has highly glycosylated thrombospondin repeat (TSR) domains.
32109505	4	62	gly	N-glycosylation	463:477	arg1	TRPM8 channel	TRPM8 channel				PUBTATOR		TRPM8 channel	79054		This work focuses on the N-glycosylation of TRPM8 channel that was previously studied by our group in relation to proliferation and migration of tumoral cells.
29237830	18	21	gly	glycosylated	2756:2767	arg1	glycosylated DG	glycosylated DG				Cterm		DG	1605		In endothelial cells that express low levels of glycosylated DG, both receptors can promote LASV entry.
33577335	5	8	gly	glycoforms	821:830	arg1	three IL-17A glycoforms	three IL-17A glycoforms				PUBTATOR		IL-17A	3605		A comparison of three IL-17A glycoforms in a normal human dermal fibroblast (NHDF) assay reveals dose-dependent interleukin-6-inducing activities in all cases, wherein the glycoform with sialyl undecasaccharides displays much weaker stimulatory effect than that of the GlcNAc- or GlcNAc(β1→4)GlcNAc-modified proteins.
30940748	9	40	gly	glycosylation	1226:1238	arg1	eIF4G	eIF4G				PUBTATOR		eIF4G	1981		The differential glycosylation of eIF4A and eIF4G appears to be regulated in the initiation complex to fine-tune protein synthesis.
30940748	9	40	gly	glycosylation	1226:1238	arg1	eIF4A	eIF4A				PUBTATOR		eIF4A	1974		The differential glycosylation of eIF4A and eIF4G appears to be regulated in the initiation complex to fine-tune protein synthesis.
32784866	5	10	gly	glycans	803:809	arg1	individual chains	chains			glycans	OGER		chains	P17813		The distribution of glycans on individual chains was also affected, with the γ chain, responsible for physiological functions of fibrinogen (such as coagulation and platelet aggregation), being most prone to these alterations.
31501520	5	1	gly	PKM2	739:742	arg1	O-GlcNAcylation	PKM2			O-GlcNAcylation	PUBTATOR		PKM2	5315		Under high glucose conditions, PKM2 is a target of OGA-associated acetyltransferase activity, which facilitates O-GlcNAcylation of PKM2 by O-GlcNAc transferase (OGT).
30593635	1	6	gly	glycoproteins	236:248	arg1	E1	envelope glycoproteins 1 and 2 (E1 and E2				PUBTATOR		envelope glycoproteins 1 and 2 (E1 and E2	6080		Posttranslational modifications (PTMs) are often required for proper folding and physiological function of proteins, including the envelope glycoproteins 1 and 2 (E1 and E2) of hepatitis C virus (HCV).
30593635	1	6	gly	glycoproteins	236:248	arg1	the envelope glycoproteins 1 and 2	envelope glycoproteins 1 and 2 (E1 and E2				PUBTATOR		envelope glycoproteins 1 and 2 (E1 and E2	6080		Posttranslational modifications (PTMs) are often required for proper folding and physiological function of proteins, including the envelope glycoproteins 1 and 2 (E1 and E2) of hepatitis C virus (HCV).
30593635	1	6	gly	glycoproteins	236:248	arg1	the envelope glycoproteins 1 and 2	envelope glycoproteins 1 and 2 (E1 and E2				PUBTATOR		envelope glycoproteins 1 and 2 (E1 and E2	6080		Posttranslational modifications (PTMs) are often required for proper folding and physiological function of proteins, including the envelope glycoproteins 1 and 2 (E1 and E2) of hepatitis C virus (HCV).
34631661	13	84	gly	glycosylation	2381:2393	arg1	recombinant human spike proteins	recombinant human spike proteins				PUBTATOR		spike proteins	43740568		Collectively, these data underscore the importance of characterizing the site-specific glycosylation of recombinant human spike proteins from HEK and CHO cells in order to better understand the impact of the production host on this complex and important protein used in research, diagnostics and vaccines.
32938717	3	73	gly	attached	600:607	arg1	the catalytic subunit Stt3 AND a high-affinity epitope tag	the catalytic subunit Stt3			a high-affinity epitope tag	PUBTATOR		Stt3	852862		Here, we established a purification method for mutated OSTs using a high-affinity epitope tag attached to the catalytic subunit Stt3, from yeast cells co-expressing the WT OST to support growth.
30919021	9	31	gly	glycosylation	1116:1128	arg1	P4HA1	P4HA1				PUBTATOR		P4HA1	18451		These results suggest that N-linked glycosylation of P4HA1 can direct hydroxylation at specific proline residues and affect collagen maturation.
31527085	0	8	gly	O-GlcNAcylation	0:14	arg1	sOGT	sOGT			O-GlcNAcylation	Cterm		sOGT	8473		O-GlcNAcylation of Thr12/Ser56 in short-form O-GlcNAc transferase (sOGT) regulates its substrate selectivity.
34213308	5	41	gly	glycosylated	794:805	arg1	a fully glycosylated spike	a fully glycosylated spike				PUBTATOR		spike	43740568		Molecular dynamics simulations of a fully glycosylated spike support a model of steric restrictions that shape enzymatic processing of the glycans.
30881698	4	28	gly	glycoprotein	656:667	arg1	Ribonuclease B	Ribonuclease B				Cterm		Ribonuclease B			Ribonuclease B was used as a model glycoprotein to compare N-glycans released by the free and immobilized enzyme.
29577901	8	10	gly	sites	1318:1322	arg1	the short isoform sOGT	OGT			sites	PUBTATOR		OGT	108155		We also map four new O-GlcNAc sites in the short isoform sOGT: S391, T393, S399 and S437 in the TPRs 11-13 domain.
29681862	12	107	gly	eNOS	2313:2316	arg1	O-GlcNAcylation	eNOS			O-GlcNAcylation	PUBTATOR		eNOS	24600		These data indicate that O-GlcNAcylation contributes to metabolic syndrome-induced PVAT dysfunction and that O-GlcNAcylation of eNOS may be targeted in the development of novel therapies for vascular dysfunction in conditions associated with hyperglycemia.
32461612	3	65	gly	glycosylated	421:432	arg1	Coronavirus S proteins	Coronavirus S proteins				Cterm		Coronavirus S proteins	43740568		Coronavirus S proteins are extensively glycosylated, encoding around 66-87 N-linked glycosylation sites per trimeric spike.
30205382	8	64	gly	modified	1476:1483	arg1	STAT3 AND O-GlcNAcylation	STAT3			O-GlcNAcylation	PUBTATOR		STAT3	25125		Immunoprecipitation revealed that STAT3 was modified by O-GlcNAcylation and phosphorylation simultaneously.
32719555	4	22	gly	glycoforms	969:978	arg1	MUC1	MUC1				PUBTATOR		MUC1	4582		In addition, O-glycosylation-competent bacteria were able to generate an antigenically authentic Tn-MUC1 glycoform that exhibited reactivity with antibody 5E5, which specifically recognizes cancer-associated glycoforms of MUC1.
32719555	4	43	gly	glycoform	866:874	arg1	an antigenically authentic Tn-MUC1 glycoform	an antigenically authentic Tn-MUC1 glycoform				PUBTATOR		MUC1	4582		In addition, O-glycosylation-competent bacteria were able to generate an antigenically authentic Tn-MUC1 glycoform that exhibited reactivity with antibody 5E5, which specifically recognizes cancer-associated glycoforms of MUC1.
30127001	9	46	gly	site	1495:1498	arg1	serine 435			serine 435	serine 435		SpecificSite			serine 435	Mutation of the O-Glc modification site on EGF11 (serine 435) in combination with sensitizing O-fucose mutations in EGF8 or EGF12 affected cell-surface presentation of NOTCH1 or reduced activation of NOTCH1 by Delta-like1, respectively.
34717971	0	47	gly	Glycosylation	0:12	arg1	an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic	an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic				OGER		Expression-enhanced SARS	P49591		Glycosylation and Serological Reactivity of an Expression-enhanced SARS-CoV-2 Viral Spike Mimetic.
33610554	9	5	gly	structures	1332:1341	arg1	N-Cdh	Cdh			structures	OGER		Cdh	Q8NE62		In addition, site-specific changes in the N-glycan structures in the extracellular domain of N-Cdh were detected, which positively impact on homotypic interactions.
32817316	4	59	gly	glycosylation	621:633	arg1	SLP-5818	SLP				PUBTATOR		SLP	100418288		Herein, we analyze the glycosylation pattern of three SLPs, SLP-8348, SLP-8321, and SLP-5818, and explore how these patterns impact their recognition by C-type lectin receptors and the immunomodulatory effect of the L. kefiri SLPs on antigen-presenting cells.
32817316	4	59	gly	glycosylation	621:633	arg1	three SLPs	SLPs, SLP				PUBTATOR		SLPs, SLP	100418288		Herein, we analyze the glycosylation pattern of three SLPs, SLP-8348, SLP-8321, and SLP-5818, and explore how these patterns impact their recognition by C-type lectin receptors and the immunomodulatory effect of the L. kefiri SLPs on antigen-presenting cells.
30566828	7	55	gly	N-glycans	838:846	arg1	CTRP12	CTRP12			N-glycans	PUBTATOR		CTRP12	388581		Complex-type N-glycans on CTRP12 blocked cleavage by the Golgi-localized furin.
29526322	9	24	gly	de-glycosylated	1255:1269	arg1	de-glycosylated NCX3	de-glycosylated NCX3				PUBTATOR		NCX3	6547		This was accompanied by accumulation of de-glycosylated NCX3 in the cytosol (that is in the ER), where it transported calcium ions (Ca2+) from the cytosol to the ER.
31300553	8	7	part_of	Ser-61	1673:1678	arg1	eIF4G1	eIF4G1		Ser-61		PUBTATOR	SpecificSite	eIF4G1	208643	Ser-61	Furthermore, our results reveal that OGT O-GlcNAc-modifies eIF4G1 at Ser-61 and that this modification is critical for eIF4G1 protein stability.
30054538	0	26	gly	sialylation	62:72	arg1	PrPSc	PrPSc				PUBTATOR		PrPSc	19122		Inflammatory response of microglia to prions is controlled by sialylation of PrPSc.
30054538	0	86	gly	PrPSc	77:81	arg1	sialylation	PrPSc			sialylation	PUBTATOR		PrPSc	19122		Inflammatory response of microglia to prions is controlled by sialylation of PrPSc.
29038508	6	49	gly	glycosylation	958:970	arg1	Fz8	Fz8				PUBTATOR		Fz8	Q9H461		OTG bound specifically to Frizzled8 (Fz8) receptor and caused retention of Fz8 in the endoplasmic reticulum possibly by preventing N-linked glycosylation of Fz8.
29315243	7	51	gly	Runx2	1315:1319	arg1	O-GlcNAcylation	Runx2			O-GlcNAcylation	PUBTATOR		Runx2	12393		Cell treatment with high glucose, glucosamine or N-acetylglucosamine increased O-GlcNAcylation of Runx2 and the total levels of O-GlcNAcylated proteins, which led to a decrease in the transcriptional activity of Runx2, expression levels of osteogenic marker genes (Runx2, osterix, alkaline phosphatase, and type I collagen), and activity of alkaline phosphatase.
34110173	0	72	gly	Glycosylation	39:51	arg1	Erythropoietin	Erythropoietin				PUBTATOR		Erythropoietin	2056		An Integrated Strategy Reveals Complex Glycosylation of Erythropoietin Using Mass Spectrometry.
29526322	7	14	gly	Glycosylation	858:870	arg1	NCX3	NCX3				PUBTATOR		NCX3	6547		Glycosylation of NCX3 at the N45 site was required for targeting the protein to the plasma membrane, and the N45 site functioned as an on-off switch for the translocation of NCX3 to either the plasma membrane or the membrane of the ER.
30420690	3	12	gly	modified	598:605	arg3	GLI2 AND O-GlcNAcylation	GLI2			O-GlcNAcylation	PUBTATOR		GLI2	2736		In elevated glucose conditions, we determined that the Hedgehog pathway transcription factors, GLI1 and GLI2, are modified by O-GlcNAcylation.
30420690	3	12	gly	modified	598:605	arg1	GLI1 AND O-GlcNAcylation	GLI1			O-GlcNAcylation	PUBTATOR		GLI1	2735		In elevated glucose conditions, we determined that the Hedgehog pathway transcription factors, GLI1 and GLI2, are modified by O-GlcNAcylation.
34229070	2	83	gly	O-glycosylation	346:360	arg1	APP	APP				OGER		APP	P05067		As an O-glycosylated protein, O-glycosylation of APP is considered to be related to Aβ generation.
28187132	1	20	gly	O-glycosylation	107:121	arg1	serum immunoglobulin A1 (IgA1)	serum immunoglobulin A1 (IgA1)				PUBTATOR		IgA1	P01876		Aberrant O-glycosylation of serum immunoglobulin A1 (IgA1) represents a heritable pathogenic defect in IgA nephropathy, the most common form of glomerulonephritis worldwide, but specific genetic factors involved in its determination are not known.
29665418	6	62	part_of	Mbp	1036:1038	arg1	N50 = 461,652 bp	614 Mbp		N50 = 461,652 bp		OGER	SpecificSite	614 Mbp	P13727	N50 	The present genome assembly consists of 5040 contigs (N50 = 461,652 bp) and a total size of 614 Mbp, of which 8.5% of the genome sequence encode known repeated elements.
31168022	3	32	gly	glycoprotein	369:380	arg1	GP	GP				PUBTATOR		GP	55819		MLS128 mAb inhibited cell growth and bound to a 110 kDa glycoprotein (GP) in LS180 and HT29 colon cancer cells.
32827291	0	35	gly	N-glycosylation	0:14	arg1	the human β1,4-galactosyltransferase 4	the human β1,4-galactosyltransferase 4				PUBTATOR		1,4-galactosyltransferase 4	8702		N-glycosylation of the human β1,4-galactosyltransferase 4 is crucial for its activity and Golgi localization.
29886537	7	17	gly	status	1122:1127	arg1	PrPSc	PrPSc			status	PUBTATOR		PrPSc	19122		The current chapter describes the procedure for the analysis of sialylation status of PrPSc from various sources including central nervous system, secondary lymphoid organs, cultured cells, or PrPSc produced in Protein Misfolding Cyclic Amplification.
29886537	7	45	gly	PrPSc	1132:1136	arg1	sialylation status	PrPSc			sialylation status	PUBTATOR		PrPSc	19122		The current chapter describes the procedure for the analysis of sialylation status of PrPSc from various sources including central nervous system, secondary lymphoid organs, cultured cells, or PrPSc produced in Protein Misfolding Cyclic Amplification.
29886537	7	55	gly	sialylation	1110:1120	arg1	PrPSc	PrPSc				PUBTATOR		PrPSc	19122		The current chapter describes the procedure for the analysis of sialylation status of PrPSc from various sources including central nervous system, secondary lymphoid organs, cultured cells, or PrPSc produced in Protein Misfolding Cyclic Amplification.
33377107	1	29	gly	glycosylation	195:207	arg1	SARS-CoV-2 spike protein	SARS-CoV-2 spike protein				PUBTATOR		spike protein	43740568		This protocol describes an integrated approach for analyzing site-specific N- and O-linked glycosylation of SARS-CoV-2 spike protein by mass spectrometry.
31622635	1	50	gly	glycoprotein	123:134	arg1	Bile-salt stimulate lipase	Bile-salt stimulate lipase				PUBTATOR		Bile-salt stimulate lipase	1056		Bile-salt stimulate lipase (BSSL) is a glycoprotein found in human milk and blood that can potently bind DC-SIGN.
33073996	6	75	part_of	PD-L1	946:950	arg1	the N219 site	PD-L1		the N219 site		PUBTATOR	SpecificSite	PD-L1	29126	N219 site	Molecular modeling of PD-L1/PD-1 interaction with N-glycans suggests that glycans at the N219 site of PD-L1 and N74 and N116 of PD-1 may be involved in glycan-glycan interactions, but the impact of this potential interaction on the protein function remains at this point unknown.
33073996	6	75	part_of	PD-L1	946:950	arg1	N74	PD-L1		N74		PUBTATOR	SpecificSite	PD-L1	29126	N74 and N116	Molecular modeling of PD-L1/PD-1 interaction with N-glycans suggests that glycans at the N219 site of PD-L1 and N74 and N116 of PD-1 may be involved in glycan-glycan interactions, but the impact of this potential interaction on the protein function remains at this point unknown.
33073996	6	12	part_of	PD-1	972:975	arg1	N74	PD-1		N74 and N116		PUBTATOR	SpecificSite	PD-1	5133	N74 and N116	Molecular modeling of PD-L1/PD-1 interaction with N-glycans suggests that glycans at the N219 site of PD-L1 and N74 and N116 of PD-1 may be involved in glycan-glycan interactions, but the impact of this potential interaction on the protein function remains at this point unknown.
29402915	7	58	gly	glycosylation	1340:1352	arg1	cubilin protein	cubilin protein				PUBTATOR		cubilin protein	8029		Quantitative mass spectrometry and mutagenesis demonstrated that N-linked glycosylation of at least 4 residues of cubilin protein was required for its surface targeting.
33462887	2	38	gly	glycosylation	354:366	arg1	DC-SIGN	DC-SIGN				OGER		DC-SIGN	Q9NNX6		How these recognition events take place with different viruses is not clear and the effects of glycosylation on the folding and stability of DC-SIGN have not been reported.
31511323	5	58	gly	N-glycosylated	844:857	arg1	β2	β2				PUBTATOR		2	170589		Using heterologous expression in polarized Madin-Darby canine kidney cells, we show that β2 is N-glycosylated in vivo and in vitro at residues 42, 66, and 74, becoming sialylated only at Asn-42.
31511323	6	20	gly	glycosylation	1058:1070	arg1	efficient β2 trafficking	efficient β2 trafficking				PUBTATOR		2	170589		We found that fully nonglycosylated β2 was mostly retained in the endoplasmic reticulum, indicating that N-linked glycosylation is required for efficient β2 trafficking to the apical plasma membrane.
31511323	6	83	gly	nonglycosylated	964:978	arg1	fully nonglycosylated β2	fully nonglycosylated β2				PUBTATOR		2	170589		We found that fully nonglycosylated β2 was mostly retained in the endoplasmic reticulum, indicating that N-linked glycosylation is required for efficient β2 trafficking to the apical plasma membrane.
30775959	7	66	gly	AF10T	846:850	arg1	carbohydrate active enzymes	AF10T			carbohydrate active enzymes	Cterm		AF10T			The genome of strain AF10T was 6.14 Mbp in size and encoded a wide repertoire of carbohydrate active enzymes.
31600726	9	49	gly	glycoforms	1545:1554	arg1	FSH glycoforms	FSH glycoforms				PUBTATOR		FSH	14308		Our results, therefore, indicate that FSH glycoforms are bioactive in isolated murine follicles.
31178836	5	28	gly	glycan	1004:1009	arg1	gp160	gp160			glycan	PUBTATOR		gp160	2028		Shorter V1 length, less potential glycan and a lower ratio of NXT: NXS in gp160 were observed in the first five time points compared to that from the last time points, as well that from the Chinese B_database.
31178836	5	99	gly	NXT	1032:1034	arg1	less potential glycan	NXT			less potential glycan	PUBTATOR		NXT	29107		Shorter V1 length, less potential glycan and a lower ratio of NXT: NXS in gp160 were observed in the first five time points compared to that from the last time points, as well that from the Chinese B_database.
30127001	3	42	gly	NOTCH1	497:502	arg1	Epidermal Growth Factor-like (EGF) repeat 11	NOTCH1			Epidermal Growth Factor-like (EGF) repeat 11	OGER		NOTCH1	P46531		This serine occurs between conserved cysteines 3 and 4 of Epidermal Growth Factor-like (EGF) repeat 11 of NOTCH1, a site distinct from those modified by protein O-glucosyltransferase 1 (POGLUT1), suggesting that a different enzyme is responsible.
31231989	10	37	gly	transferrin	1456:1466	arg1	the N-linked glycans	transferrin			the N-linked glycans	OGER		transferrin	P02787		Partial loss of galactose and sialic acid of the N-linked glycans of serum transferrin was observed.
35140700	8	61	gly	IgG	1138:1140	arg1	The fine carbohydrate structures	IgG			The fine carbohydrate structures	Cterm		IgG			The fine carbohydrate structures of IgG were confirmed by matrix-assisted laser desorption/ionization-quadrupole ion trap-time of flight-mass spectrometry (MALDI-TOF-MS).
30919021	0	61	gly	glycans	25:31	arg1	prolyl 4-hydroxylase subunit	prolyl 4-hydroxylase subunit α1			glycans	PUBTATOR		prolyl 4-hydroxylase subunit α1	18451		Ascorbate inducible N259 glycans on prolyl 4-hydroxylase subunit α1 promote hydroxylation and secretion of type I collagen.
33273015	4	83	gly	carries	484:490	arg1	nMPO AND both characteristic under-processed and hyper-truncated glycans	nMPO			both characteristic under-processed and hyper-truncated glycans	Cterm		nMPO	P05164		Mass spectrometry demonstrated that nMPO carries both characteristic under-processed and hyper-truncated glycans.
28100911	1	56	gly	glycoprotein	261:272	arg1	ABCG2	ABCG2				PUBTATOR		ABCG2	9429		A recent genome-wide association study (GWAS) for dental caries nominated the chromosomal region 4q21 near ABCG2, PKD2 and the SIBLING (small integrin-binding ligand N-linked glycoprotein) gene family.
30956133	4	6	gly	α2,6-sialyltransferase	414:435	arg1	ST6Gal-I	-galactoside α2,6-sialyltransferase 1			ST6Gal-I	PUBTATOR		-galactoside α2,6-sialyltransferase 1	6480		We identify distinct functions of exomeres mediated by two of their cargo, the β-galactoside α2,6-sialyltransferase 1 (ST6Gal-I) that α2,6- sialylates N-glycans, and the EGFR ligand, amphiregulin (AREG).
30956133	4	8	gly	β-galactoside	400:412	arg1	ST6Gal-I	-galactoside α2,6-sialyltransferase 1			ST6Gal-I	PUBTATOR		-galactoside α2,6-sialyltransferase 1	6480		We identify distinct functions of exomeres mediated by two of their cargo, the β-galactoside α2,6-sialyltransferase 1 (ST6Gal-I) that α2,6- sialylates N-glycans, and the EGFR ligand, amphiregulin (AREG).
30956133	4	45	gly	sialylates	461:470	arg1	the β-galactoside α2,6-sialyltransferase 1	the β-galactoside α2,6-sialyltransferase 1				PUBTATOR		-galactoside α2,6-sialyltransferase 1	6480		We identify distinct functions of exomeres mediated by two of their cargo, the β-galactoside α2,6-sialyltransferase 1 (ST6Gal-I) that α2,6- sialylates N-glycans, and the EGFR ligand, amphiregulin (AREG).
30944176	11	21	gly	glycosylated	1930:1941	arg1	a viral envelope protein	a viral envelope protein				PUBTATOR		envelope protein	64006		All isolates from recent outbreaks encode a viral envelope protein that is glycosylated, whereas many historical ZIKV strains lack this glycosylation.
28748269	5	51	gly	had	695:697	arg1	BPIFB1 AND N-linked glycan	BPIFB1			N-linked glycan	PUBTATOR		BPIFB1	228801		BPIFB1 had N-linked glycan that reacted with Aleuria aurantia lectin, which caused two types of spots with a slightly different pI and molecular weight.
30991145	2	54	gly	glycoprotein	422:433	arg1	The G protein	The G protein				OGER		G protein			The G protein, which harbors the major antigenic determinants of IHNV, is an envelope glycoprotein that plays an important role in both pathogenicity and immunogenicity of IHNV.
33177111	7	25	gly	CD55	952:955	arg1	N-	CD55			N-	OGER		CD55	P08174		Detailed analyses of N- and O-linked oligosaccharides of CD55 released from scramble or ST3GAL1 siRNA-treated breast cancer cells by tandem mass spectrometry revealed that the N-glycan profile was not affected by ST3GAL1 silencing.
33177111	7	25	gly	CD55	952:955	arg1	O-linked oligosaccharides	CD55			O-linked oligosaccharides	OGER		CD55	P08174		Detailed analyses of N- and O-linked oligosaccharides of CD55 released from scramble or ST3GAL1 siRNA-treated breast cancer cells by tandem mass spectrometry revealed that the N-glycan profile was not affected by ST3GAL1 silencing.
34343291	3	48	gly	receptor	554:561	arg1	N-glycans	insulin receptor			N-glycans	PUBTATOR		insulin receptor	3643		One such example is the development of insulin resistance, which has been attributed to the removal of sialic acid residues from N-glycans of insulin receptor (IR) from various experimental studies.
34192331	7	5	gly	IgGs	1041:1044	arg1	multibranched N-glycans	IgGs			multibranched N-glycans	Cterm		IgGs			In this study, IgGs with multibranched N-glycans on the Fc region were prepared by using a combination of the glycosynthase/oxazoline substrate-based N-glycan remodeling technique and successive reactions with glycosyltransferases.
30150325	7	45	part_of	ATX1	977:980	arg1	Ser947	ATX1		Ser947		OGER	AminoAcid	ATX1	P54253	Ser947	SEC transfers an O-GlcNAc group on Ser947 of ATX1, which resides in the SET domain, thereby activating ATX1.
31667130	7	111	gly	N-glycosylation	1178:1192	arg1	β-catenin	β-catenin				PUBTATOR		-catenin	84353		It was confirmed that APPB inhibits N-glycosylation of β-catenin at 2.5 nM concentration.
33340519	7	57	gly	deglycosylation	1025:1039	arg1	ACE2	ACE2				OGER		ACE2	Q9BYF1		In contrast, deglycosylation of ACE2 did not influence SARS-CoV-2 binding.
29784879	7	64	gly	EDEM3	1287:1291	arg1	the mannose-trimming activity	EDEM3			the mannose-trimming activity	PUBTATOR		EDEM3	80267		In a defined in vitro system consisting of recombinant proteins purified from HEK293 cells, the mannose-trimming activity of EDEM3 toward the model misfolded substrate, the glycoprotein T-cell receptor α locus (TCRα), was reconstituted only when ERp46 had established a covalent interaction with EDEM3.
29070692	1	63	gly	glycoproteins	313:325	arg1	Gc	Gc				Cterm		Gc			Heartland virus (HRTV) is an emerging human pathogen that belongs to the newly defined family Phenuiviridae, order Bunyavirales Gn and Gc are two viral surface glycoproteins encoded by the M segment and are required for early events during infection.
31604106	4	129	gly	O-glycosylation	575:589	arg1	recombinant hCG protein expression	hCG protein				PUBTATOR		hCG protein	93659		The effects of O-glycosylation on recombinant hCG protein expression were assessed by adding O-glycan precursors and overexpressing and knocking down key regulatory genes of O-glycan precursor synthesis and O-glycan sugar chain synthesis or hydrolases.
30633504	5	27	gly	N-glycosylation	832:846	arg1	RNase 1	RNase 1				PUBTATOR		RNase 1	6035		We found that the N-glycosylation of RNase 1 at any position attenuates its catalytic activity but enhances both its thermostability and its resistance to proteolysis.
31600726	6	68	gly	glycoforms	890:899	arg1	FSH glycoforms	FSH glycoforms				PUBTATOR		FSH	14308		However, the direct effects of FSH glycoforms on the mouse ovarian follicle have not yet been determined.
30919021	5	2	gly	glycosylation	577:589	arg1	P4HA1	P4HA1				PUBTATOR		P4HA1	18451		N259 glycosylation on P4HA1 correlates with enhanced pepsin-resistant collagen 1α2 secretion.
29672582	2	44	gly	IgG	491:493	arg1	G0 N-glycan	IgG			G0 N-glycan	PUBTATOR		IgG	668542		Many reports show that altered IgG glycosylation, especially IgG with agalactosylated N-linked glycan (G0 N-glycan), have proinflammatory roles including complement activation, implicated in the pathogenesis of various inflammatory diseases.
29672582	2	44	gly	IgG	491:493	arg1	agalactosylated N-linked glycan	IgG			agalactosylated N-linked glycan	PUBTATOR		IgG	668542		Many reports show that altered IgG glycosylation, especially IgG with agalactosylated N-linked glycan (G0 N-glycan), have proinflammatory roles including complement activation, implicated in the pathogenesis of various inflammatory diseases.
31783892	2	3	gly	glycosylation	193:205	arg1	PD-1	PD-1				OGER		PD-1	Q15116		Reducing N-linked glycosylation of PD-1 may decrease PD-1 expression and relieve its inhibitory effects on CAR-T cells.
29030255	9	113	gly	glycosylation	1114:1126	arg1	pufferfish CA VI	pufferfish CA VI				PUBTATOR		CA VI	765		Three potential N-linked glycosylation sites and two cysteine residues (Cys-28 and Cys-209) that are likely to form one disulfide bond were present in pufferfish CA VI.
31616924	5	3	gly	O-glycosylated	850:863	arg1	APOE	APOE				PUBTATOR		APOE	348		APOE is O-glycosylated at several sites: Thr8, Thr18, Thr194, Ser197, Thr289, Ser290 and Ser296.
32168410	8	40	gly	deglycosylated	968:981	arg1	deglycosylated and native FXIII-B	deglycosylated and native FXIII-B				PUBTATOR		FXIII-B	2165		The clearance of deglycosylated and native FXIII-B from plasma was compared in FXIII-B knock out mice.
31306420	11	83	gly	glycosylated	1686:1697	arg1	NYF	NYF, SYP				PUBTATOR		NYF, SYP	6855		Glycosylated NYT exhibited similar avian virulence properties as NYS, but resulted in higher mosquito oral infectivity than glycosylated NYS and nonglycosylated, NYP, NYF, SYP and KYS mutants.
32172531	7	63	gly	nonglycosylated	1085:1099	arg1	nonglycosylated hERG channels	nonglycosylated hERG channels				PUBTATOR		hERG channels	2078		Compared with normal glycosylated channels, nonglycosylated hERG channels were also more susceptible to cleavage mediated by CAPN, which was present in the medium of human embryonic kidney cells under normal culture conditions.
31266804	8	38	gly	-glycoprotein	1411:1423	arg1	the mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase	the mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase				PUBTATOR		mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase	4245		Deletion of the mannosyl (α-1,3-)-glycoprotein β-1,2-N-acetylglucosaminyltransferase (MGAT1), necessary for the generation of complex N-linked glycans, abrogated TRPC6 gain-of-function variant-mediated Ca2+ influx and extracellular signal-regulated kinase activation in HEK cells, but failed to diminish cytotoxicity in cultured podocytes.
33581334	5	15	gly	contains	561:568	arg1	OGP AND 11,633 site-specific O-glycans	OGP		9354 O-glycosylation sites	11,633 site-specific O-glycans	PUBTATOR	Site	OGP	5016	sites	OGP contains 9354 O-glycosylation sites and 11,633 site-specific O-glycans mapping to 2133 O-glycoproteins, and it is the largest O-glycoprotein repository thus far.
30479582	4	1	gly	glycopeptides	777:789	arg1	rabbit IgGs	rabbit IgGs				Cterm		IgGs			Here, we have devised a unified model to predict the retention behavior of glycopeptides from human IgGs and applied this to the analysis of glycopeptides from rabbit IgGs.
30479582	4	45	gly	glycopeptides	711:723	arg1	human IgGs	human IgGs				Cterm		IgGs			Here, we have devised a unified model to predict the retention behavior of glycopeptides from human IgGs and applied this to the analysis of glycopeptides from rabbit IgGs.
31527085	7	30	gly	domain	854:859	arg1	sOGT	sOGT			domain	Cterm		sOGT	8473		We identified six O-GlcNAc sites in the tetratricopeptide repeat domain in sOGT, with Thr12 and Ser56 being two "key" sites.
31527085	4	48	gly	O-GlcNAcylation	505:519	arg1	ncOGT	ncOGT			O-GlcNAcylation	Cterm		ncOGT	8473		Moreover, O-GlcNAcylation of Ser389 in ncOGT (1036 amino acids) affects its nuclear translocation in HeLa cells.
33947960	4	21	gly	modified	862:869	arg3	ErbB2 AND both α2,6- and α2,3-sialylated glycan structures	ErbB2			both α2,6- and α2,3-sialylated glycan structures	PUBTATOR		ErbB2	2064		Here, we demonstrate that ErbB2 is modified with both α2,6- and α2,3-sialylated glycan structures in GC clinical specimens.
34631661	4	20	gly	glycopeptides	1052:1064	arg1	the S protein	the S protein				OGER		S protein	Q15517		To further evaluate the sialic acid linkages presenting on S protein, a two-step amidation process, employing dimethylamine and ammonium hydroxide reactions in a solid support system, was developed to differentially modify the sialic acid linkages on the glycans and glycopeptides from the S protein.
34631661	4	28	gly	protein	1077:1083	arg1	glycans	S protein			glycans	OGER		S protein	Q15517		To further evaluate the sialic acid linkages presenting on S protein, a two-step amidation process, employing dimethylamine and ammonium hydroxide reactions in a solid support system, was developed to differentially modify the sialic acid linkages on the glycans and glycopeptides from the S protein.
29263294	5	44	gly	attachment	881:890	arg1	the fatty acid transporter CD36 AND O-linked N-acetylglucosamine	the fatty acid transporter CD36			O-linked N-acetylglucosamine	OGER		CD36	P16671		The changes in glucose and fatty acid metabolism are interlinked via a Nox4-ATF4-dependent increase in the hexosamine biosynthetic pathway, which mediates the attachment of O-linked N-acetylglucosamine (O-GlcNAcylation) to the fatty acid transporter CD36 and enhances fatty acid utilization.
29886537	2	40	gly	glycosylation	278:290	arg1	amyloid precursor protein	amyloid precursor protein				OGER		amyloid precursor protein	P05067		They include N-linked glycosylation of the prion protein and amyloid precursor protein, phosphorylation of tau and α-synuclein.
27643667	7	75	gly	deglycosylation	626:640	arg1	MPO	MPO				PUBTATOR		MPO	4353		Three de-glycosylated MPOs were used to assay the influence of deglycosylation on microbicidal effect of MPO.
30205382	9	78	gly	JAK2-Tyr705STAT3-VEGF	1647:1667	arg1	the JAK2-Tyr705STAT3-VEGF pathway	JAK2			the JAK2-Tyr705STAT3-VEGF pathway	PUBTATOR		JAK2	3717		Next, we observed that overexpression of O-GlcNAcylation could relieve human RVEC apoptosis related to the JAK2-Tyr705STAT3-VEGF pathway.
29577901	0	35	gly	receptor-α	33:42	arg1	O-GlcNAc site-mapping	X receptor			O-GlcNAc site-mapping	OGER		X receptor	Q9UBH6		O-GlcNAc site-mapping of liver X receptor-α and O-GlcNAc transferase.
32469948	7	40	gly	β-1,2-N-acetylglucosaminyltransferase	1029:1065	arg1	mannosylation	N-acetylglucosaminyltransferase			mannosylation	OGER		N-acetylglucosaminyltransferase	Q8N0V5		In addition, we knocked in the MdsI (α-1,2-mannosidase) gene to reduce mannosylation and the GnTI (β-1,2-N-acetylglucosaminyltransferase I) and GnTII genes to produce human N-glycan structures.
32553689	1	15	gly	glycosylation	144:156	arg1	serum IgG	serum IgG				Cterm		IgG			BACKGROUND Alternative glycosylation of serum IgG has been shown to be closely associated with colorectal cancer (CRC).
32692906	1	13	gly	O-glycosylated	253:266	arg1	DR5	DR5				PUBTATOR		DR5	8795		The TNF-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in cells by signaling through the O-glycosylated death receptors (DR4 and DR5), but the sensitivity to TRAIL-induced apoptosis of cells varies, and the attributes of this phenomenon are complex.
32692906	1	13	gly	O-glycosylated	253:266	arg1	DR4	DR4				PUBTATOR		DR4	3126		The TNF-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in cells by signaling through the O-glycosylated death receptors (DR4 and DR5), but the sensitivity to TRAIL-induced apoptosis of cells varies, and the attributes of this phenomenon are complex.
30158294	8	95	gly	N-glycosylation	1108:1122	arg1	SERINC5	SERINC5				PUBTATOR		SERINC5	256987		Our results demonstrate that N294 is the major site of N-glycosylation in SERINC5.
34813786	4	55	gly	Gal	663:665	arg1	core 1 O-glycan	Gal			core 1 O-glycan	OGER		Gal	Q8N6F7		Interestingly, C. savignyi sialyltransferase exhibited effectively Neu5Ac transfer to core 1 O-glycan, Gal β(1,3)GalNAc, compared to orthologous human glycosyltransferase.
31101650	5	92	gly	under-glycosylated	1071:1088	arg1	furin	furin				PUBTATOR		furin	5045		Providing cDNA for Golgi-resident proprotein convertase subtilisin/kexin type 5a (PCSK5a) and furin cDNA to wild-type and mutant cells produced under-glycosylated forms of PCSK5a, but not furin, in cells lacking STT3A.
29454068	9	15	gly	modified	1119:1126	arg1	ribosomal RACK1 AND O-GlcNAc	ribosomal RACK1			O-GlcNAc	PUBTATOR		RACK1	14694		RESULTS: We found that ribosomal RACK1 was highly modified by O-GlcNAc at Ser122.
32461612	4	25	gly	density	553:559	arg1	MERS S	S			density	Cterm		S	43740568		Here, we reveal a specific area of high glycan density on MERS S that results in the formation of oligomannose-type glycan clusters, which were absent on SARS and HKU1 CoVs.
31110306	3	47	gly	N-glycosylation	496:510	arg1	a stably expressed IgG	a stably expressed IgG				Cterm		IgG			In this study, we engineered Chinese hamster ovary cells with synthetic genetic circuits to tune N-glycosylation of a stably expressed IgG.
34379416	7	64	gly	unglycosylated	1266:1279	arg1	hPDI	hPDI				OGER		hPDI	P07237		In addition, we compare our results on yPDI with structural information of homologous proteins such as human PDI (hPDI), which is natively unglycosylated.
34379416	7	64	gly	unglycosylated	1266:1279	arg1	human PDI	human PDI				PUBTATOR		PDI	64714		In addition, we compare our results on yPDI with structural information of homologous proteins such as human PDI (hPDI), which is natively unglycosylated.
31831633	8	17	gly	glycoform	1356:1364	arg1	the altered MUC1-sTn glycoform	the altered MUC1-sTn glycoform				OGER		MUC1	P15941		Immunostaining of ulcerative colitis and CACC tissue samples confirmed the elevated number of M2-like macrophages as well as high expression of ST6GALNAC1 and the altered MUC1-sTn glycoform on colon cells.
30487280	1	33	gly	glycoprotein	229:240	arg1	native-like, soluble envelope glycoprotein SOSIP trimers	native-like, soluble envelope glycoprotein SOSIP trimers				PUBTATOR		envelope glycoprotein SOSIP	100616444		In HIV-1 vaccine research, native-like, soluble envelope glycoprotein SOSIP trimers are widely used for immunizing animals.
28528272	13	24	gly	unglycosylated	1935:1948	arg1	both glycosylated and unglycosylated cystatin E/M	both glycosylated and unglycosylated cystatin E/M				PUBTATOR		cystatin E/M	1474		Contrary to the importance of legumain glycosylation, both glycosylated and unglycosylated cystatin E/M showed similar capacity to inhibit legumain.
28528272	13	38	gly	glycosylated	1918:1929	arg1	both glycosylated and unglycosylated cystatin E/M	both glycosylated and unglycosylated cystatin E/M				PUBTATOR		cystatin E/M	1474		Contrary to the importance of legumain glycosylation, both glycosylated and unglycosylated cystatin E/M showed similar capacity to inhibit legumain.
31544308	8	77	gly	vitamin	1158:1164	arg1	glycan	vitamin B			glycan	Cterm		vitamin B			RESULTS Predicted microbial function showed lower amino acid, bioenergetics and lipid pathways, with functions related to vitamin B, glycan, xenobiotic metabolism, DNA/RNA synthesis, in cirrhotics from Turkey compared to the USA.
34213308	3	8	gly	glycosylation	387:399	arg1	recombinant SARS-CoV-2 spike proteins	recombinant SARS-CoV-2 spike proteins				PUBTATOR		spike proteins	43740568		Here, we investigate the glycosylation of recombinant SARS-CoV-2 spike proteins from five different laboratories and compare them against S protein from infectious virus, cultured in Vero cells.
28229220	1	59	gly	glycoprotein	142:153	arg1	PURPOSE HepaCAM	PURPOSE HepaCAM				PUBTATOR		|PURPOSE
HepaCAM|	Q14CZ8		PURPOSE HepaCAM, an N-linked glycoprotein that encodes a member of the immunoglobulin superfamily, has been reported to be a tumor suppressor gene that mediates diverse cellular bio-functions.
31186110	8	73	gly	glycosylated	1320:1331	arg1	The purified glycosylated IFN α2b	The purified glycosylated IFN α2b				PUBTATOR		IFN α2b	3440		The purified glycosylated IFN α2b was biologically active, inhibiting the viral replication of HCV and HEV at 85% and 66%, respectively.
31306674	1	17	gly	glycoproteins	236:248	arg1	viral N-linked glycoproteins	viral N-linked glycoproteins				Cterm		N-linked glycoproteins	3458		The antiviral mechanism of action of iminosugars against many enveloped viruses is hypothesized to be a consequence of misfolding of viral N-linked glycoproteins through inhibition of host endoplasmic reticulum α-glucosidase enzymes.
32784866	3	45	gly	glycosylation	562:574	arg1	native fibrinogen	native fibrinogen				PUBTATOR		fibrinogen	2244		Taking into consideration that fibrinogen mediates these processes, we isolated fibrinogen from the plasma from patients with ESRD on peritoneal dialysis (ESRD-PD), and examined glycosylation of native fibrinogen and its subunits by lectin-based microarray and lectin blotting.
32784866	3	45	gly	glycosylation	562:574	arg1	its subunits	its subunits				OGER		subunits	P17813		Taking into consideration that fibrinogen mediates these processes, we isolated fibrinogen from the plasma from patients with ESRD on peritoneal dialysis (ESRD-PD), and examined glycosylation of native fibrinogen and its subunits by lectin-based microarray and lectin blotting.
30581149	11	82	gly	HHM-glycoproteins	1831:1847	arg1	CONCLUSION Defined recombinant HHM-glycoproteins	CONCLUSION Defined recombinant HHM-glycoproteins				OGER		HHM	O95273		CONCLUSION Defined recombinant HHM-glycoproteins resembling carbohydrate-specific IgE epitopes from plants, venoms and mites were engineered which made it possible to discriminate carbohydrate- from peptide-specific IgE reactivity.
29780502	4	48	gly	O-mannosylated	784:797	arg1	a model IDP	a model IDP				OGER		IDP	O75874		Here, we synthesized variants of a model IDP, specifically a natively O-mannosylated linker from a fungal enzyme, with α-O-linked mannose, glucose, and galactose moieties, along with a non-glycosylated linker.
31831633	3	29	gly	glycosylation	502:514	arg1	MUC1	MUC1				OGER		MUC1	P15941		It is not known what causes changes in glycosylation of MUC1.
30633504	2	31	gly	N-glycosylation	312:326	arg1	RNase 1	RNase 1				PUBTATOR		RNase 1	6035		The effect of N-glycosylation on the structure and function of RNase 1 is unknown.
31336250	6	76	gly	aglycosylated	1503:1515	arg1	aglycosylated Fc	aglycosylated Fc				Cterm		Fc			All mutations in this aglycosylated Fc variant were derived from previously identified beneficial mutations for engineered aglycosylated Fc variants as opposed to glycosylated variants, suggesting that significantly different sets of beneficial mutations are necessary to improve the effector function of aglycosylated Fc.
28976803	5	4	gly	mannosylation	1182:1194	arg1	phospholipase B1	phospholipase B1				PUBTATOR		phospholipase B1	665270		Phenotypic comparison of the arg1Δ and kcs1Δ deletion mutants (both PP-IP5-deficient) reveals that arg1Δ has the most deleterious phenotype: while PP-IP5 is essential for metabolic and stress adaptation in both mutant strains, PP-IP5 is dispensable for virulence-associated functions such as capsule production, cell wall organization, and normal N-linked mannosylation of the virulence factor, phospholipase B1, as these phenotypes were defective only in arg1Δ.
27690717	6	2	gly	N-glycosylation	1230:1244	arg1	β2 subunits	β2 subunits				PUBTATOR		2 subunits	23545		Our results suggest that N-glycosylation of β2 subunits plays crucial roles in imparting functional heterogeneity of BK channels, and is potentially involved in the pathological phenotypes of carbohydrate metabolic diseases.
34670086	0	64	gly	Glycosylation	24:36	arg1	the SARS-CoV-2 Spike	the SARS-CoV-2 Spike				PUBTATOR		Spike	43740568		Suppression of O-Linked Glycosylation of the SARS-CoV-2 Spike by Quaternary Structural Restraints.
30348809	8	58	gly	N-glycosylation	1013:1027	arg1	CSF3R	CSF3R				PUBTATOR		CSF3R	1441		Mutation of the N610 site prevented membrane-proximal N-glycosylation of CSF3R, which then drove ligand-independent cellular expansion.
32109505	6	11	gly	glycosylation	765:777	arg1	TRPM8	TRPM8				PUBTATOR		TRPM8	79054		The glycosylation state of TRPM8 in cells untreated and treated with a deglycosylating agent was addressed with Terahertz (THz) spectroscopy.
36303733	5	25	gly	protein	977:983	arg1	The N-glycan biosynthesis network	spike protein			The N-glycan biosynthesis network	PUBTATOR		spike protein	43740568		Results: The N-glycan biosynthesis network of SARS-CoV-2 spike protein shows an elaborate enzymatic pathway with several intermediate glycans, along with the ones identified by mass spectrometric studies.
34869209	5	11	gly	glycosylation	583:595	arg1	the HEK293 recombinant spike RBD and S1 domains	the HEK293 recombinant spike RBD and S1 domains				PUBTATOR		spike RBD	43740568		In this study, we have characterized the site-specific glycosylation patterns of the HEK293 recombinant spike RBD and S1 domains as well as the intact spike derived from the whole virus produced in Vero cells.
34869209	5	11	gly	glycosylation	583:595	arg1	the intact spike	the intact spike				PUBTATOR		spike	43740568		In this study, we have characterized the site-specific glycosylation patterns of the HEK293 recombinant spike RBD and S1 domains as well as the intact spike derived from the whole virus produced in Vero cells.
30158294	14	21	gly	glycosylated	2296:2307	arg1	SERINC5	SERINC5				PUBTATOR		SERINC5	256987		Here we show that SERINC5 is a glycosylated protein and that N-glycosylation is important for its steady state expression.
30713024	6	23	gly	OGT-dependent	937:949	arg1	O-GlcNAcF3	OGT			O-GlcNAcF3	PUBTATOR		OGT	108155		Further, NIH3T3 cells interfered with OGT (siOGT) showed significant decreasing of O-GlcNAc levels with Ac4GlcNAcF3 treatment, indicating O-GlcNAcF3 was an OGT-dependent modification.
29530619	11	3	gly	modification	1835:1846	arg3	Nav1.5 AND Excessive O-GlcNAc modification	Nav1.5			Excessive O-GlcNAc modification	PUBTATOR		Nav1.5	6331		Excessive O-GlcNAc modification of Nav1.5 is a novel signaling event, which may be an underlying contributing factor for the development of the arrhythmogenesis in DH.
29530619	11	15	gly	Nav1.5	1851:1856	arg1	Excessive O-GlcNAc modification	Nav1.5			Excessive O-GlcNAc modification	PUBTATOR		Nav1.5	6331		Excessive O-GlcNAc modification of Nav1.5 is a novel signaling event, which may be an underlying contributing factor for the development of the arrhythmogenesis in DH.
29980609	4	30	gly	glycoproteins	755:767	arg1	molecular determinants	AICL glycoproteins			molecular determinants	PUBTATOR		AICL glycoproteins	9976		In this study, we characterize molecular determinants of AICL glycoproteins that cause intracellular retention, thereby controlling AICL surface expression.
28614667	8	46	part_of	CTR	1582:1584	arg1	CTR N130	CTR		CTR N130		PUBTATOR	SpecificSite	CTR	799	N130	Characterization of peptide-binding affinities of purified N → Q CTR ECD glycan site mutants combined with PNGase F and Endo H treatment strategies and mass spectrometry to define the glycan species indicated that a single GlcNAc residue at CTR N130 was responsible for the peptide affinity enhancement.
30633504	1	57	gly	N-glycosylated	255:268	arg1	the archetypal enzyme RNase A. RNase 1	the archetypal enzyme RNase A. RNase 1				PUBTATOR		RNase 1	6035		Ribonuclease 1 (RNase 1) is the most prevalent human homologue of the archetypal enzyme RNase A. RNase 1 contains sequons for N-linked glycosylation at Asn34, Asn76, and Asn88 and is N-glycosylated at all three sites in vivo.
33664400	5	21	gly	non-glycosylated	612:627	arg1	non-glycosylated CD44	non-glycosylated CD44				OGER		CD44	P16070		We find that non-glycosylated CD44 favors the canonical sub-micromolar binding site, while glycosylated CD44 binds hyaluronan with an entirely different micromolar binding site.
33664400	5	29	gly	glycosylated	690:701	arg1	glycosylated CD44	glycosylated CD44				OGER		CD44	P16070		We find that non-glycosylated CD44 favors the canonical sub-micromolar binding site, while glycosylated CD44 binds hyaluronan with an entirely different micromolar binding site.
29717387	4	7	gly	N-glycosylation	416:430	arg1	PPARγ	PPARγ				PUBTATOR		PPAR	5468		In this study, the N-glycosylation of PPARγ, as well as two N-linked glycosylation sites in its DNA binding domain (DBD), was identified.
30581149	4	85	gly	non-glycosylated	781:796	arg1	HHM 0	HHM 0				OGER		HHM	O95273		HHM 1 and HHM 2 containing one or two N-glycosylation sites were expressed in baculovirus-infected High-Five™ insect cells and a non-glycosylated version (HHM 0) was obtained by mutating the glycosylation motif.
30221662	10	23	gly	membrane	2380:2387	arg1	the O‑GlcNAc‑modified substrate protein SNAP29	vesicle‑associated membrane protein 8			the O‑GlcNAc‑modified substrate protein SNAP29	PUBTATOR		vesicle‑associated membrane protein 8	83730		Finally, co‑immunoprecipitation was used to determine the role of the O‑GlcNAc‑modified substrate protein SNAP29, which acted as an SNAP29‑syntaxin‑17 (STX17)‑vesicle‑associated membrane protein 8 (VAMP8) complex during disease progression.
30221662	10	30	gly	VAMP8	2400:2404	arg1	the O‑GlcNAc‑modified substrate protein SNAP29	8 (VAMP8			the O‑GlcNAc‑modified substrate protein SNAP29	PUBTATOR		8 (VAMP8	83730		Finally, co‑immunoprecipitation was used to determine the role of the O‑GlcNAc‑modified substrate protein SNAP29, which acted as an SNAP29‑syntaxin‑17 (STX17)‑vesicle‑associated membrane protein 8 (VAMP8) complex during disease progression.
30221662	10	86	gly	protein	2389:2395	arg1	the O‑GlcNAc‑modified substrate protein SNAP29	vesicle‑associated membrane protein 8			the O‑GlcNAc‑modified substrate protein SNAP29	PUBTATOR		vesicle‑associated membrane protein 8	83730		Finally, co‑immunoprecipitation was used to determine the role of the O‑GlcNAc‑modified substrate protein SNAP29, which acted as an SNAP29‑syntaxin‑17 (STX17)‑vesicle‑associated membrane protein 8 (VAMP8) complex during disease progression.
30221662	10	91	gly	‑vesicle‑associated	2360:2378	arg1	the O‑GlcNAc‑modified substrate protein SNAP29	vesicle‑associated membrane protein 8			the O‑GlcNAc‑modified substrate protein SNAP29	PUBTATOR		vesicle‑associated membrane protein 8	83730		Finally, co‑immunoprecipitation was used to determine the role of the O‑GlcNAc‑modified substrate protein SNAP29, which acted as an SNAP29‑syntaxin‑17 (STX17)‑vesicle‑associated membrane protein 8 (VAMP8) complex during disease progression.
29402915	6	52	gly	glycosylation	1197:1209	arg1	cubilin	cubilin				PUBTATOR		cubilin	8029		Notably, the interaction between cubilin and amnionless was not sufficient, but amnionless-mediated glycosylation of cubilin was necessary for their surface expression.
29454068	10	52	gly	RACK1	1170:1174	arg1	O-GlcNAcylation	RACK1			O-GlcNAcylation	PUBTATOR		RACK1	14694		O-GlcNAcylation of RACK1 enhanced its protein stability, ribosome binding and interaction with PKCβII (PRKCB), leading to increased eukaryotic translation initiation factor 4E phosphorylation and translation of potent oncogenes in HCC cells.
32168410	3	21	gly	linked	373:378	arg1	FXIII-B AND the glycan structures	FXIII-B			the glycan structures	PUBTATOR		FXIII-B	2165		OBJECTIVE To reveal the glycan structures linked to FXIII-B, to design a method for deglycosylating the native protein, to find out if deglycosylation influences the dimeric structure of FXIII-B and its clearance from the circulation.
33177111	10	66	gly	sialylation	1614:1624	arg1	CD55	CD55				OGER		CD55	P08174		These data demonstrated that ST3GAL1-mediated O-linked sialylation of CD55 acts like an immune checkpoint molecule for cancer cells to evade immune attack and that inhibition of ST3GAL1 is a potential strategy to block CD55-mediated immune evasion.
33177111	10	88	gly	CD55	1629:1632	arg1	ST3GAL1-mediated O-linked sialylation	CD55			ST3GAL1-mediated O-linked sialylation	OGER		CD55	P08174		These data demonstrated that ST3GAL1-mediated O-linked sialylation of CD55 acts like an immune checkpoint molecule for cancer cells to evade immune attack and that inhibition of ST3GAL1 is a potential strategy to block CD55-mediated immune evasion.
35140700	2	52	gly	glycosylation	253:265	arg1	IgG	IgG				Cterm		IgG			The glycosylation patterns of IgG play a critical role in regulating the biological function and stability of IgG involved in the pathophysiology of many AIDs.
28528272	3	29	gly	unglycosylated	394:407	arg1	cystatin E/M	cystatin E/M				PUBTATOR		cystatin E/M	1474		In this study both glycosylated and unglycosylated forms of legumain and cystatin E/M were studied.
28528272	3	29	gly	unglycosylated	394:407	arg1	legumain	legumain				OGER		legumain	Q99538		In this study both glycosylated and unglycosylated forms of legumain and cystatin E/M were studied.
28528272	3	33	gly	glycosylated	377:388	arg1	cystatin E/M	cystatin E/M				PUBTATOR		cystatin E/M	1474		In this study both glycosylated and unglycosylated forms of legumain and cystatin E/M were studied.
28528272	3	33	gly	glycosylated	377:388	arg1	legumain	legumain				OGER		legumain	Q99538		In this study both glycosylated and unglycosylated forms of legumain and cystatin E/M were studied.
31181726	1	9	gly	P-glycoprotein	238:251	arg1	P-glycoprotein	P-glycoprotein				PUBTATOR		P-glycoprotein	5243		A series of novel 7,9-O-linked macrocyclic taxoids together with modification at the C2 position were synthesized, and their cytotoxicities against drug-sensitive and P-glycoprotein and βIII-tubulin overexpressed drug-resistant cancer cell lines were evaluated.
34379416	4	14	gly	glycosylated	670:681	arg1	yPDI	yPDI				Cterm		yPDI	64714		Yeast PDI (yPDI) from Saccharomyces cerevisiae is glycosylated at asparagine side chains and the knowledge of its five modified sites enables a realistic computational modeling.
34379416	4	14	gly	glycosylated	670:681	arg1	Yeast PDI	Yeast PDI				PUBTATOR		PDI	64714		Yeast PDI (yPDI) from Saccharomyces cerevisiae is glycosylated at asparagine side chains and the knowledge of its five modified sites enables a realistic computational modeling.